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Abstract 




Melanoma, the deadliest form of skin cancer, is characterized by aberrant 
hyperactivation of the ERK mitogen-activated protein kinase signaling pathway. Genetic lesions 
in the core components of the RAS-RAF-MEK-ERK protein kinase cascade as well as its 
upstream regulators are key features of melanoma progression and drug resistance. MEK, the 
central kinase within the cascade, is constitutively activated by many upstream oncogenic 
events and is an important drug target. MEK inhibition in combination with BRAF inhibition is the 
standard of care for treating BRAFV600E melanoma. However, not all BRAFV600E melanomas 
respond to these inhibitors, and those that do respond eventually acquire resistance. To better 
understand mechanisms of MEK inhibitor susceptibility and MEK regulation in BRAFV600E 
melanoma, I performed a loss-of-function screen to identify kinases and phosphatases that 
modulate sensitivity to two clinical MEK1/2 inhibitors. In this screen, I identified PPP6C, the 
catalytic subunit of protein phosphatase 6 (PP6), as a factor promoting sensitivity to MEK 
inhibition. I established PPP6C as a major MEK phosphatase in cells exhibiting oncogenic ERK 
pathway activation. Recruitment of MEK to PPP6C occurs through an interaction with its 
associated regulatory subunits. Loss of PPP6C causes hyperphosphorylation of MEK at both 
activating and crosstalk phosphorylation sites, promoting signaling through the ERK pathway 
and decreasing sensitivity to the growth inhibitory effects of MEK inhibitors.  
Consistent with its role in regulating ERK signaling, PPP6C is frequently mutated in 
melanoma, as is MEK1.  I found that recurrent melanoma-associated PPP6C mutations cause 
MEK hyperphosphorylation and ERK signaling hyperactivation when expressed in cells. 
Recurrent MEK1 mutations all promote MEK1 kinase activity but are activated by different 
mechanisms of action. The elevated MEK activity associated with PPP6C mutations or MEK1 
mutations suggests that they promote disease by a common mechanism: activating the core 
oncogenic pathway driving melanoma. 
Collectively, our studies identify novel modulators of susceptibility to ERK pathway 
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targeted cancer therapies, including PPP6C, a key negative regulator of ERK signaling, and 
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CHAPTER 1: INTRODUCTION 
1.1 ERK MAPK Signaling  
The extracellular signal-regulated kinase (ERK) mitogen activated protein kinase 
(MAPK) signaling cascade regulates essential cellular functions in response to growth 
factors and cytokines in many cell types1-3. This pathway is canonically activated through 
receptor tyrosine kinases (RTK) activation of RAS GTPases (NRAS, KRAS, and HRAS), 
which directly bind and activate RAF kinases (BRAF, CRAF, and ARAF) (Figure 1.1A). 
Activated RAF kinases dimerize to phosphorylate and activate MEK1/2, which 
phosphorylate and activate ERK1/2. ERK1/2 phosphorylate substrates that act as 
effectors mediating the functional output of the pathway. With hundreds of target 
phosphorylation sites on cytoplasmic and nuclear substrates, ERK signaling mediates a 
diverse range of responses which includes cell differentiation, survival, proliferation, 
growth, migration, and metabolism. Specific cellular responses are determined by tightly 
regulated mechanisms: signal duration and intensity, cell-type specific substrate 
expression, scaffold proteins, and localization of cascade components. Further 
regulation is provided by the greater complex signaling network surrounding the ERK 
signaling cascade which includes feedback regulation mechanisms and crosstalk with 
peripheral pathways such as the PI3K-AKT pathway3-5 (Figure 1.1A). Deregulation of the 
pathway, primarily through mutations or amplification of genes, leads to various disease 
states, namely cancer. 
 
1.1.1 Oncogenic ERK MAPK Signaling  
Because the ERK signaling pathway has the highest frequency of alterations 
across all cancer types, the ERK pathway is one of the most extensively studied signaling 
pathways6,7. Constitutive activation of ERK signaling in these cancers not only can lead 
to uncontrolled cell proliferation and survival, but also tumor invasion, metastasis, and 
angiogenesis. Activating genetic mutations in RAS and RAF are the most prevalent. RAS 
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mutations occur in 19% of all cancers, primarily at codons 12, 13, or 61 and favor the 
GTP-bound, active state of RAS8. The V600E mutation in BRAF is by far the dominant 
BRAF mutation, making up 95% of all BRAF mutations9,10. V600K, V600D and V600R 
mutations occur but at a much lower frequencies11. The substitution of a larger charged 
residue for V600 on the BRAF activation loop, destabilizes V600 interactions that 
maintain the DFG motif in an inactive conformation and presumably mimics 
conformational changes promoted by activation loop phosphorylation at T59912. 
Recurrent non-V600 BRAF mutations, though not as common, occur at higher 
frequencies in some cancer types such as lung cancers where ~50% of BRAF mutations 
are non-V600 mutations13,14. Non-V600 BRAF mutations are activated by different 
mechanisms and consequently exhibit different drug sensitivities15,16. More recently, 
loss-of-function mutations in Neurofibromin 1 (NF1), a GTPase activating protein (GAP) 
that downregulates RAS activity, have been appreciated as driver mutations in lung 
adenocarcinoma, melanoma, and glioma17-19. NF1-mutations in melanoma commonly co-
occur with mutations in pathway-related genes like RASA2, another GAP that 
downregulates RAS activity, and SOS1, a guanine nucleotide exchange factor (GEF) that 
promotes RAS activation18. Activating mutations in MEK and ERK occur at low 
frequencies in head and neck cancer, lung squamous cell carcinoma, cervical 
carcinoma, colorectal cancer, and melanoma7,18,19. Many of the less common ERK 
pathway mutations are acquired resistance mechanisms that emerge as secondary 
pathway mutations to overcome pathway suppression by ERK pathway inhibitors, 
described in detail below.  
 The hallmarks of cancer described by Hanahan and Weinberg are the key cellular 
capabilities required for tumor development and progression20. Constitutive activation of 
the ERK MAPK pathway provides signaling to support several of these hallmark 
capabilities. Examining the normal functions of ERK signaling provides insights into how 
ERK signaling contributes to tumorigenesis. For example, one key role of the ERK 
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pathway in cell proliferation is controlling the G1 to S phase transition in the cell cycle. 
Continuous or repetitive pulses of ERK pathway activation results in progression of cells 
from G1 to S phase, initiating the growth factor independent phase of cell cycle 
progression21-23. ERK phosphorylates the ETS family of transcription factors, including 
ELK1, which induce the expression of transcription factors JUN, FOS, and MYC, which 
regulate early G1 phase and late G1 phase genes for irreversible S phase entry. ERK 
pathway activation provides pro-survival signals by inhibiting pro-apoptotic factors (BIM, 
BAD, BIK) through direct phosphorylation by ERK or downstream kinases and also by 
stimulating antiapoptotic proteins23-27 (MCL-1). Constitutive oncogenic ERK signaling, 
through these normally highly regulated functions, can sustain proliferative signaling and 
resist cell death for tumor growth. Other less defined potential mechanisms of ERK 
signaling in cancer include the promotion of the Warburg effect for deregulated cellular 
metabolism28,29 and regulation of matrix metalloproteinases MMP-2 and MMP-9 to 
activate invasion and metastasis30-32. Many potential physiological mechanisms by which 
ERK signaling influences tumorigenesis have been investigated and described in great 
detail.  The pleiotropic nature of oncogenic ERK signaling underscores why the ERK 
signaling pathway is the most frequently altered in melanoma. 
 
1.1.2 Genetic Landscape of Driver Mutations in Melanoma 
With the advancement of high-throughput genomic sequencing technology and 
large-scale initiatives in tumor characterization of melanoma patient cohorts, the full 
range of somatic mutations observed in melanoma have been recorded for hundreds of 
melanoma tumors18,19,33-37. These genomic landscape studies confirmed the prevalence 
of ERK pathway mutations in melanoma and classified the disease into 4 genomic 
subtypes based on the driver mutation present in the ERK pathway7,18,19 (Figure 1.1B). 
The largest subtype (~50%) includes tumors harboring BRAF mutations. Three 
additional subtypes—NRAS mutant (~25%), NF1 mutant (~15%), and “triple wild-type” 
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make up the remaining 50% of melanomas (Figure 1.2). BRAF, NRAS, and NF1 mutations 
occur largely mutually exclusively.  
While BRAF, NRAS, and NF1 are thought to be the major genes driving melanoma 
progression, their individual mutation alone is insufficient for malignant transformation of 
melanocytic nevi38. Additional mutations must occur in conjunction with these driver 
mutations to promote transformation. However, because melanoma has a high somatic 
mutational burden, identifying driver mutations from inconsequential passenger 
mutations is challenging, especially with the abundance of sequencing datasets for 
melanoma tumors available. Thus far, mutational frequency is the main criterion used to 
predict potential driver genes. This approach to driver gene discovery not only overlooks 
infrequently occurring driver mutations, but also does not offer insight into the functional 
or mechanistic consequences of mutations. Because extensive studies are required to 
fully understand how identified mutations drive oncogenesis, the rate at which genomic 
datasets are generated far exceeds their analysis for oncogene or tumor suppressor 
functions. For example, TP53, CDKN2A, KIT, RAC1, and PTEN are frequently mutated 
genes whose oncogenic functions have been well elucidated in the context of 
melanoma18,33-35 (Figure 1.2). Conversely, PPP6C, ARID2, IDH1, KMT2C, and DDX3X are 
also significant frequently mutated genes whose contributions to melanoma progression 
have not been thoroughly investigated. While some of these potential clinically important 
therapeutic targets are implicated in known oncogenic pathways, others have yet 
unclear associations with oncogenic signaling. Establishing how these secondary driver 
mutations alter oncogenic signaling can aid in predicting disease  progression and drug 
response, leading to the further advancement of precision medicine. 
 
1.2 Pathway Inhibitors in Melanoma  
 Targeted therapeutic approaches have been a major breakthrough for treating 
melanoma patients and for personalized medicine. The development of ERK pathway  
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Figure 1.1 Normal and Oncogenic ERK MAP Kinase Pathway 
(A) Simplified schematic of the ERK MAPK signaling pathway (yellow) and PI3K-AKT 
signaling pathway (orange). Blue lines indicate cross-talk between pathways. Red lines 
indicate negative feedback via ERK. 





Figure 1.2 Mutational Frequencies of Genes in Melanoma 
List of selected mutated genes in patient samples from non-redundant melanoma and 




inhibitors (MAPKi) was motivated by the growing appreciation of oncogenic ERK 
signaling activation in melanoma (Figure 1.1B). In the clinic, inhibitors targeting core 
components of the ERK signaling pathway results in improved response rates and 
prolonged progression free survival. The efficacy of these inhibitors has shifted first line 
therapy options away from chemotherapy to targeted therapy for BRAFV600E melanoma. 
While many of the MAPKi described below have revolutionized cancer treatment, there 
is still much to be done for longer progression-free survival or curative responses.  
 
1.2.1 BRAF Inhibitors (BRAFi) 
The discovery of the prevalence of BRAFV600E mutations and the establishment of 
constitutive ERK signaling in the majority of melanomas identified BRAF as a key driver 
gene and favorable therapeutic target9,10,41 . siRNA and shRNA knockdown of BRAF 
result in loss of MEK and ERK phosphorylation and the induction of cell cycle arrest and 
death in BRAFV600E melanoma cell lines and xenograft models41-43, confirming the critical 
role of BRAFV600E in melanoma tumor growth and validating BRAFV600E as a drug target. 
Small molecule ATP competitive inhibitors for BRAF have been developed and used as 
research tools and investigated for clinical intervention. Sorafenib (BAY43-09006), a 
multitarget kinase inhibitor with a wide spectrum of cellular targets, was initially 
investigated in various melanoma clinical trials due to its activity against BRAFV600E. 
However, its nonselective inhibition of various RTKs as well as CRAF and wild-type BRAF 
makes it difficult to interpret which targets promote antitumor activity. In clinical trials, 
sorafenib monotherapy and combination therapy have largely resulted in insufficient 
benefit for melanoma patients44-49. More selective BRAF inhibitors (BRAFi) have been 
successful in the clinic. Vemurafenib (PLX4032), like its precursor PLX4720, was 
developed using a structure guided discovery approach to preferentially inhibit the 
mutant form of BRAF50,51. This selectivity for BRAFV600E induces cell death in BRAFV600E 
cells and tumor regression in BRAFV600E tumor xenograft models43,52,53. Vemurafenib has 
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had dramatic results in BRAFV600E melanoma patients, producing impressive rapid 
response rates and progression free survival with minimal treatment-related toxicity51,54-
57. Vemurafenib was the first FDA approved BRAFi. Dabrafenib and encorafenib are also 
approved BRAFi shown to have similar efficacies in melanoma patients58-60. Despite the 
rapid response and early clinical benefits to BRAFi treatment, advanced metastatic 
melanoma patients acquire resistance shortly after starting BRAFi treatment, with median 
time to disease progression of 5-7 months55-57,61. Mechanisms of resistance and 
strategies to combat resistance are discussed below.  
 While the described BRAFi inhibit ERK signaling in BRAFV600E cells, they 
unexpectedly enhance ERK signaling in wild-type BRAF cells, promoting cell growth and 
proliferation62-64. This paradoxical ERK activation is caused by BRAFi binding to one 
protomer of a BRAF/CRAF heterodimer or homodimer followed by transactivation of the 
drug-free RAF molecule. In the context of BRAFV600E cells, BRAF exists as an active 
monomer, minimizing transactivation of dimers. In the context of RAS mutations, 
increased wild-type BRAF expression, or increased upstream receptor activation, the 
increased signaling activity promotes RAF dimerization for transactivation upon BRAFi 
binding. In patients, paradoxical ERK activation can induce cutaneous squamous cell 
carcinoma and keratoacanthoma tumors commonly harboring RAS mutations54,65,66. 
Thus, depending on the genomic and signaling context, BRAFi can have inhibitory or 
activating effects on ERK signaling, underscoring the importance of genotyping or 
mutational profiling of tumors for patient selection.  
The next generation of BRAFi, known as “paradox breakers”, have been 
developed to address the issue of paradoxical ERK activation67. PLX7904 and PLX8396 
inhibit both monomeric BRAFV600E and dimeric wild-type BRAF, as well as non-V600E 
mutant forms of BRAF. PLX8396 has shown greater efficacy in inhibiting ERK signaling 
and inducing apoptosis in wild-type BRAF, BRAFV600E, or BRAF splice-variant expressing 
melanoma cell lines, xenografts, and patient derived explant models68. Ongoing phase 
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I/IIA clinical trials thus far show promising results and a more favorable safety profile for 
the use of PLX8394 in patients with advanced solid tumors69.  
 
1.2.2 MEK Inhibitors (MEKi) 
MEK inhibitors (MEKi) were the first inhibitors of the MAPK pathway developed 
and originally intended to be in vitro research tools for dissecting the MAPK signal 
transduction pathway70,71. The development of MEKi for the treatment of cancer was 
motivated by MEK’s position as a bottleneck for ERK signaling, integrating upstream 
oncogenic signaling from overactive RAS, RAFs, and RTKs, where the majority of 
pathway activating mutations and mechanisms occur, to activate ERK (Figure 1.1B). 
Unlike most kinase inhibitors, MEKi are highly selective, allosteric, non-ATP competitive 
inhibitors. Improving on the poor bioavailability, potency, and tolerability of early MEKi 
research compounds, several newer MEKi are FDA approved or are being investigated 
in ongoing clinical trials72,73. Trametinib (GSK1120212), the first FDA approved MEKi, 
inhibits phosphorylation of MEK by RAF, attenuating ERK signaling and inducing cell 
death in BRAFV600E melanoma cells and xenografts74. Although trametinib monotherapy 
improved overall survival rates and progression free survival of BRAFV600E mutant 
melanoma patients compared to conventional chemotherapy75,76, it did not show 
improvement over BRAFi treatment. This may partially be due to dose-limiting toxicity 
because MEKi target MEK in all cells and not a specific mutant form found in only cancer 
cells as with BRAFV600E.  
The emergence of MAPK re-activation as the primary mechanism of BRAFi 
resistance (described in 1.3) led to proposing MEK inhibition as a strategy to combat 
BRAFi resistance through targeting the immediate downstream effector of BRAF77,78. As 
anticipated, MEKi in combination with BRAFi does show improvement over BRAFi 
monotherapy61,79,80. The therapeutic effect of the combination therapy is synergistic while 
reducing the toxicity with either alone81,82. As a first line therapy, 72.3% of patients were 
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free of disease progression at 6 months with BRAFi and MEKi versus only 55.4% with 
BRAFi alone. Trametinib/dabrafenib, binimetinib/encorafenib, and 
cobimetinib/vemurafenib, all FDA approved MEKi/BRAFi treatment options for BRAFV600E 
melanoma, result in improved median time to progression from ~7.3 months with BRAFi 
monotherapy to ~11.9 months83. As adjuvant therapy in patients with resected stage III 
BRAFV600E melanoma, MEKi/BRAFi combination therapy prolongs survival without relapse 
or distant metastasis, resulting in 52% of patients without relapse at 5 years compared 
to 36% of patients with placebo84. MEKi/BRAFi combinations are the current standard of 
care for advanced BRAFV600E melanoma85. While the combination delays the emergence 
of drug resistance, as evidenced by the significantly improved progression free survival, 
resistance through similar mechanisms as BRAFi monotherapy resistance remains a 
critical obstacle in the use of targeted therapy. 
MEKi are in on-going preclinical and clinical investigation for combinatorial 
treatment with other targeted therapies and immunotherapies73,86. Novel MEKi treatment 
combinations are expected to benefit the treatment of different melanoma genetic 
subtypes and other cancer types. 
 
1.2.3 ERK inhibitors (ERKi) 
 The major mechanisms of resistance to MEKi/BRAFi combination and 
monotherapy reactivate MAPK signaling87-89 (Figure 1.3). Inhibition downstream of the 
majority of these resistance mechanisms (Figure 1.2) at ERK was proposed to overcome 
or further delay resistance. Additionally, ERK inhibitors (ERKi) have the potential to be 
rational treatment options for BRAFi-resistant BRAFV600E melanoma and other cancers 
driven by MAPK activity but insensitive to BRAF and MEK inhibition.  
In preclinical studies, selective ATP-competitive ERKi reduce the strong 
reactivation of ERK signaling in MEKi/BRAFi resistant cells and inhibit cell growth and 
proliferation in cells and mouse xenograft models90-96. These inhibitors also have 
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antitumor activity against some wild-type BRAF and NRAS mutant cell lines in addition 
to most MEKi/BRAFi sensitive BRAFV600E cells, suggesting potential therapeutic response 
in additional patient genetic subtypes. Of the numerous ERKi under investigation in early 
clinical trials97,98, Ulixertinib (BVD-523) is the most promising, having shown partial 
responses in NRAS mutant, BRAFV600E and wild-type BRAF solid tumors, including 
melanomas99. Partial responses were also observed with the ERKi MK-8353 and 
Ravoxertinib (GDC-0994) in melanoma96 and other BRAFV600E tumors100. The mentioned 
clinical studies demonstrate early efficacy as well as acceptable safety profiles but more 
clinical trial data is necessary for a complete assessment of the clinical benefits of ERKi 
as monotherapies and combination therapies. Ongoing clinical trials are investigating 
ERKi in combination with MEKi, chemotherapies, CDK4/6 inhibitors, and anti-PD-1 
immunotherapies97,98. 
 
1.3 Melanoma Targeted Therapy Resistance 
 The use of MAPK pathway inhibitors in the clinic has significantly improved the 
treatment of melanoma and patient outcomes. Unfortunately, the rapid responses to 
BRAFi and MEKi are almost invariably short-lived due to the development of acquired 
resistance80. Of the BRAFV600E melanoma patient population, 10-20% of patients do not 
have any initial response due to intrinsic resistance. Additionally, the heterogeneity of 
tumor resistance mechanisms complicate how resistance is addressed. Not only is there 
resistance heterogeneity between patients, there are often multiple mechanisms of 
resistance within a patient or even a single tumor101. 
 
1.3.1 ERK MAPK Pathway Reactivation 
 Analyses of tumors with acquired resistance to BRAFi and/or MEKi have identified 
reactivation of the MAPK signaling pathway as the major driver of resistance87,101-104. 
Mechanisms underlying pathway reactivation are diverse but usually involve pathway 
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components (Figure 1.3). Resistance mechanisms involving alterations in BRAFV600E and 
NRAS are the most common. BRAFV600E amplification and alternative splicing are found 
in 8-30% and 13-29% of post-treatment progressive melanoma tumors, respectively101-
106. Activating mutations in NRAS are found in 8-23% of progressive tumors101-104,107,108. 
Activating mutations in KRAS are less common, occurring in 2-7% of progressive 
tumors101,104. MEK mutations occur in 3-20% of progressive tumors89,101-104,107. The 
frequency of BRAF amplification and MEK2 mutations are significantly higher in 
MEKi/BRAFi combination therapy resistance than in BRAFi monotherapy resistance89, 
suggesting these mechanisms cause the substantially greater reactivation of ERK 
signaling characteristic of combination therapy resistance. This is not surprising given 
resistance to kinase inhibitors is often associated with secondary mutations to the target 
gene. Upregulation of receptor tyrosine kinases, NF1 loss, CRAF overexpression, and 
COT (MAP3K8) upregulation are less common MAPK reactivation mechanisms 
observed in BRAFi and/or MEKi resistant tumors87,88,102,108,109.  
 Strategies to overcome MAPK reactivation-mediated resistance such as the 
implementation of intrapathway dual inhibition by BRAFi and MEKi combinations have 
only delayed the time to acquired resistance, as detailed above. While early indications 
suggest ERKi will combat resistance from MAPK reactivation, ERKi resistance 
mechanisms have not yet been identified or thoroughly investigated. Although many 
ERK1 and ERK2 mutations have been identified in mutagenesis screens for drug 
resistance110-114, ERK mutations are rare in cancers. The ERK2 E320K mutation, which 
has been observed in 27 squamous cell carcinoma patients, elevates ERK pathway 
activation in cells and confers resistance to BRAFi and MEKi but not ERKi112,113. The 
number and heterogeneity of MAPKi resistance mechanisms for MAPK reactivation 






Figure 1.3 MAPK Reactivation Mechanisms for MAPKi Resistance  
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1.3.2 PI3K-AKT Pathway Activation 
 
 ERK MAPK signaling remains inhibited in 20-30% of BRAFi and MEKi resistant 
tumors indicating the activation of alternative cell growth and survival pathways for 
resistance88,101,102. While upregulation of or activating mutations in RTKs can be a MAPK 
reactivation mechanism, it can also activate other survival pathways peripheral to the 
ERK signaling pathway for resistance. The upregulated RTKs EGFR, PDGFR, MET, and 
IGF-1R activate both the PI3K-AKT pathway and the ERK MAPK pathway108,115. The PI3K-
AKT pathway is the second core resistance pathway identified for BRAFi and MEKi 
resistance in BRAFV600E melanoma. The PI3K-AKT pathway, another central signaling 
pathway for regulating essential cellular pathways, is activated in many cancers through 
various genetic and epigenetic alterations116,117. In this pathway, activated RTKs and G 
protein-coupled receptors (GPCR) activate phosphatidylinositol 3’-kinase (PI3K), which 
phosphorylates and converts the plasma membrane lipid PIP2 to PIP3 (Figure 1.1A). PIP3 
recruits AKT and PDK1 to the cell membrane where PDK1 phosphorylates and activates 
AKT. Downstream effectors of AKT regulate cell proliferation and cell survival. In 
melanoma, PI3K-AKT signaling has been implicated in both intrinsic and acquired 
resistance118,119. Genetic alterations in the PI3K-AKT pathway can precede or succeed 
MAPKi resistance. Generally, MAPKi resistant cells either have high basal levels of 
activated AKT or increased AKT activation in response to MAPKi91. 
The most commonly detected PI3K-AKT pathway alterations in melanoma are 
copy number loss or loss-of-function mutations of PTEN, a negative regulator of the PI3K-
AKT pathway and established tumor suppressor (Figure 1.1A, 1.2). PTEN loss is 
detected in 8-20% of melanoma tumors and often co-occur with BRAFV600E 
mutations37,120,121. These PTEN alterations are found in pretreatment and/or post-
treatment progressive tumors. Although higher PTEN expression levels are associated 
with BRAFi responders, PTEN expression levels are not predictive of MAPKi 
response107,119. Mechanistically, PTEN loss mediates inhibitor resistance by suppressing 
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BIM-mediated apoptosis119. Furthermore, ERK signaling inhibition in PTEN null cells 
activates AKT signaling. This is all consistent with the decreased clinical benefit of BRAFi 
treatment for BRAFV600E melanoma patients with PTEN loss compared to BRAFV600E 
melanoma patients with wild-type PTEN. 
Other alterations within the pathway include mutations in PIK3CA, the catalytic 
subunit of PI3K and an established oncogene, and AKT, which are detected in 2-6% and 
1-2% of melanoma18,33,122, respectively. Mutations in PHLPP1, PIK3R1, and PIK3R2, 
negative regulators of the pathway, are rare (<2%) in melanoma but have been observed 
in MAPKi resistant progressive tumors101,117. Identical pathway mutations have been 
observed in other cancer types and shown to activate oncogenic signaling. Although 
there are limited studies, PI3K-AKT mutations present in MEKi/BRAFi combination 
resistant tumors were present pre-treatment as well89,123, suggesting the PI3K-AKT 
pathway may potentially have a more limited role in resistance to dual MAPK pathway 
inhibitor treatment. 
PI3K-AKT pathway alterations elicit MAPKi resistance in a complex and context-
dependent manner. These alterations occur independently and co-occur with MAPK 
activation or reactivation. Crosstalk between the two pathways likely influence how 
resistance is mediated (Figure 1.1A). Preclinical studies have demonstrated the added 
benefit and synergistic inhibition of combining PI3K inhibitors with MAPKi124,125. PI3K-AKT 
pathway inhibition can delay resistance to MEKi in BRAFV600E melanoma126. In clinical 
trials investigating pan-PI3K inhibitors with BRAFi or MEKi in BRAFV600E patients, poor 
tolerability was a major limitation127-130. Similarly, MAPKi in combination with AKT 
inhibitors showed poor tolerability and limited efficacy. 
 
1.3.3 Other Pathways in MAPKi Resistance 
 Beyond activation of the two major oncogenic signaling pathways, MAPKi 
resistance can involve other known oncogenic signaling pathways. Signal transducer 
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and activator of transcription (STAT) proteins are a family of transcription factors that 
when phosphorylated dimerize and translocate to the nucleus where they activate gene 
transcription. STAT3 is an oncogene131,132 constitutively activated in several cancers 
including melanoma133. STAT3 oncogenic function comes from its regulation of 
apoptosis inhibitors, inducers of angiogenesis, and cell cycle regulators. STAT3 is 
activated by interleukin-6 (IL-6) family cytokine receptor associated Janus Kinases 
(JAKs) as well as EGFR-activated SRC-family kinases (SFK). BRAFV600E melanoma cells 
with acquired BRAFi resistance have elevated EGFR activating phosphorylation and 
decreased EGFR negative regulatory phosphorylation accompanied by activating 
phosphorylation of its downstream effector AKT134. Consequently, phosphorylation of 
SFKs and STAT is elevated in BRAFi resistant cells, which were found to be sensitive to 
pan-SFK inhibitors and a STAT3 dimerization inhibitor. Alternatively, a subset of 
BRAFV600E cells with intrinsic resistance to BRAFi have increased autocrine IL-6 secretion 
which activates the JAK-STAT3 pathway135 to overcome ERKi signaling inhibition. 
Combining JAK inhibition with MEK inhibition suppresses STAT3 phosphorylation and 
can overcome resistance. STAT3 silencing or inhibition also overcomes acquired 
resistance and can restore BRAFi sensitivity in BRAFV600E melanoma cells136,137.  
p12-activated kinases (PAKs) become activated in cells with acquired BRAFi and 
MEKi/BRAFi resistance138. For BRAFi monotherapy resistance, phosphorylation of CRAF 
and MEK by PAKs are another mechanism for ERK MAPK reactivation. For MEKi/BRAFi 
combination resistance, PAKs activate JNK, which activates downstream targets shared 
with ERK such as ELK1, JUN, and FOS. In the context of MEKi/BRAFi resistance, PAKs 
also regulates β-catenin phosphorylation, activates mTOR signaling, and inhibits 
apoptotic signaling to mediate MAPKi drug resistance.  
 
1.3.4 Identifying Novel Resistance Mechanisms  
Numerous screening strategies have been used to identify genetic dependencies 
 17 
for MAPKi sensitivity and novel therapeutic targets. The advantage of these exploratory 
and unbiased genetic approaches is their potential to discover unexpected pathways 
involved in MAPKi resistance as well as synthetic lethal interactions that can be exploited 
in melanoma treatment. These newly identified vulnerabilities may inform biomarker-
based patient selection for MAPKi treatment. 
Pooled screening strategies model intratumor heterogeneity and the clonal 
evolution of cancer for emergence of resistance. Screens investigating MAPKi response 
in melanoma have confirmed known resistance pathways. For example, a high 
throughput functional screen expressed ~600 kinases or kinase related open reading 
frames (ORFs) in BRAFi sensitive BRAFV600E melanoma cell line to identify ORFs that 
confer resistance to BRAFi139. This systemic gain-of-function screen identified COT and 
CRAF as top candidate kinases that mediate BRAFi resistance. Establishing COT-
dependent mechanisms of MAPK reactivation, this study proposed dual intrapathway 
inhibition with RAF/MEK inhibition and RAF/COT inhibition combinations, substantiating 
the use of BRAFi and MEKi combinations in the clinic. Elevated COT expression has 
been detected in BRAFi resistant tumors (Figure 1.3). A large-scale RNA interference 
(RNAi) screen identified functional loss of NF1 as a mediator of BRAFi resistance in 
BRAFV600E melanoma, which was confirmed by the NF1 mutations present in BRAFi 
resistant tumors109. An insertional mutagenesis screen in a BRAFV600E melanoma mouse 
model identified the PI3K-AKT signaling pathway as a mediator of BRAFi resistance140.  
With the advancement of screening techniques and enrichment analysis and the 
increased availability of sgRNA and shRNA libraries, recent genetic screens have 
identified novel vulnerabilities in MAPKi resistance. Large-scale CRISPR screens in 
BRAFi resistant BRAFV600E melanoma cells and subsequent pathway enrichment analysis 
discovered a novel class of cell cycle genes (CDK6, CCND1, PSMB1, and RRM2), not 
previously linked BRAFi resistance, enriched within the 314 genes whose depletion 
sensitized cells to BRAFi141. Further characterization established that the depletion of 
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CDK6 and its regulator ETV5 restores MAPKi sensitivity. Although there are ongoing 
clinical studies investigating MAPKi and pan CDK4/6 inhibitor combinations142,143, the 
authors establish that the inhibition of CDK6, and not other CDKs, synergizes with BRAFi. 
Interestingly, CDK6 expression and up-regulation of genes functionally connected to 
CDK6 are associated with poor survival in BRAFi-treated melanoma patients. 
 In an epigenome-wide shRNA screen, knockdown of BOP1, HAT1, ING5, and 
KDM4C conferred resistance to BRAFi in a BRAFV600E mutant melanoma cell line144. The 
authors focused on Block of proliferation 1 (BOP1), which they propose downregulates 
DUSP4/6 and results in MAPK reactivation for BRAFi resistance. Analysis of paired 
melanoma patient samples before and after BRAFi treatment showed BOP1 down 
regulation in progressive tumors. Similarly, HAT1 was found to reactivate the MAPK 
pathway, and 63% of progressive tumors showed reduced HAT1 expression compared 
to patient matched MAPKi treatment naive tumors145.  
These large-scale pooled screening strategies are complicated by off-target 
effects, varying knockdown efficiencies, library complexity, selection of bioinformatic 
pipelines, and scalability for appropriate library coverage. For example, a genome-wide 
shRNA screen identified CUL3, a key protein in E3 ubiquitin ligase complexes, as a 
driver of MAPKi resistance146. However, 7 of the 9 candidate drivers identified in this 
screen did not recapitulate MAPKi resistance in validation studies. Overall, the 
described functional genetic screens were able to identify verifiable genes and 
pathways that modulate MAPKi sensitivity. Validation studies demonstrate the ability of 
these candidate therapeutic targets to overcome MAPKi resistance. More importantly, 
analysis of target gene expression in patient tumors and patient response rates 
underscore the clinical relevance of the findings from genetic screens. 
 
1.4 PPP6C in Melanoma 
 The work in this dissertation describes the identification of PPP6C as a key 
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regulator of ERK signaling in melanoma. PPP6C is a conserved essential serine-
threonine metallophosphatase related to the catalytic subunit of PP2A147. PPP6C 
functions within heterotrimeric PP6 holoenzymes consisting of a Sit4-associated protein 
(SAPS) domain regulatory subunit (PPP6R1, PPP6R2 or PPP6R3) that mediates substrate 
recruitment and an ankyrin repeat (ANKRD28, ANKRD44 or ANKRD52) subunit that may 
serve a scaffolding role148,149 (Figure 1.4A). The presence of multiple regulatory and 
scaffolding subunits defines nine potential PP6 complexes that collectively participate in 
a variety of cellular processes. 
 
1.4.1 Established PP6 Functions 
As an essential protein ubiquitously expressed in mammalian tissues, PPP6C has roles 
in key cellular functions including cell cycle progression150-152, the DNA damage 
response150,153-155, autophagy156, miRNA processing157, inflammatory response158,159, and 
antiviral immunity160. Despite the scope and diversity of signaling roles described, our 
current understanding of PPP6C functions is limited, especially when considering the 
number of PPP6C studies compared to that of its extensively studied close relative PP2A. 
Because PP2A was the first PP2A family phosphatase purified and characterized, many 
PP2A studies use okadaic acid, a pan-PP2A family phosphatase inhibitor, as a PP2A 
inhibitor and report that its biological effects are attributed to PP2A inhibition. Okadaic 
acid inhibits PP2A, PP4, and PP6 with nearly identical potency. These studies are 
reporting on the effects of collective inhibition of all three of these phosphatases and 
likely incorrectly assigning PP6 functions to PP2A. 
PPP6C has well-established roles in cell cycle progression. PP6 regulation of 
chromosome segregation and spindle assembly in mitosis is highly conserved in 
eukaryotes, from yeast to humans152,162,163. PPP6C or PPP6R1/2/3 loss results in defective 
chromosome segregation in anaphase and fragmented nuclei in telophase. PPP6C and 




Figure 1.4 PPP6C Mutations in Melanoma 
(A) PP6 heterotrimeric complexes 
(B) Frequencies of mutations in BRAF, NRAS, and NF1 co-occurring with PPP6C in 
melanoma. Data are from nonoverlapping melanoma studies in cBioportal39,40 
(C) Frequencies of PPP6C mutations reported in melanomas. Data are from nonoverlapping 




Figure 1.5 PPP6C residues mutated in melanoma mapped onto the structure of the PP2A 
catalytic subunit  
(A) Recurrently mutated PPP6C residues His55 and Arg264 are shown in cyan in stick 
representation modeled onto the crystal structure of PPP2CA161 (PDB: 2IAE). Catalytic 
metal ions are shown as pink spheres.  
(B) Arg264 maps to the interface of the PP2A catalytic subunit (blue) and the PP2A 




essential mitotic kinase, localizes to spindle poles and centromeres during mitosis upon 
associating with its binding partner TPX2. PP6 recognizes and dephosphorylates Aurora 
A-TPX2 complexes, inactivating Aurora A152. DNA-PK, a regulator of mitosis and DNA 
damage repair, localizes to centrosomes, spindles, and the midbody during mitosis. PP6 
dephosphorylation of DNA-PK during mitosis mediates mitotic exit and cytokinesis.  A 
broad phosphoproteomics study aimed to identify PP6-regulated phosphorylation 
events during mitosis confirmed PP6 regulation of chromosome segregation and spindle 
formation in protein network and pathway analysis of increased phosphorylation events 
upon PPP6C depletion165. PP6 was also found to mediate chromosome condensation, in 
part through direct dephosphorylation of the condensin 1 subunit NCAPG to activate 
condensin-1151,165. Other than in mitosis, PP6 has been reported to have roles in other 
phases of the cell cycle including the G1/S transition166,167 and S phase progression168,169 
as well as meiosis170,171. 
In DNA damage response signaling, PP6 is involved in both non-homologous end 
joining repair (NHEJ) and homology-directed repair (HDR), the two processes that fix 
DNA double-strand breaks (DSBs). Ionizing radiation (IR), which causes DSBs, induces 
the expression of PP6 subunits in cells172,173. Conversely, PP6 depletion sensitizes cells 
to IR, marked by increased phosphorylation of g-H2AX164,174,175. PPP6R1 targets PP6 to 
DNA-PK for dephosphorylation and activation of DNA-PK in NHEJ150,153,164,174,175. There is 
also evidence for DNA-PK recruitment of PP6 for dephosphorylation of g-H2AX to repair 
DSBs resulting from IR via NHEJ164. Similarly, PPP6C is recruited to DSB sites to 
dephosphorylate g-H2AX to repair DSB resulting from replication blockage via HDR155.  
 PP6 negatively regulates the canonical nuclear factor-kB (NF-kB) pathway, which 
is essential for immune and inflammatory responses. Proinflammatory cytokines like 
tumor necrosis factor-a (TNF-a) and interleukin-1b (IL-1b) stimulate TGF-b-activated 
kinase 1 (TAK1) autophosphorylation and activation, which activates IkB kinase (IKK) for 
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phosphorylation of IkBe and activation of NF-kB signaling176. PP6 associates with and 
dephosphorylates TAK1, inhibiting its activity and therefore negatively regulating its 
downstream pathways, the NF-kB pathway and MAPK signaling pathways158,177. PPP6C 
and PP6 regulatory subunits also associate with IkBe, which binds and inhibits NF-kB by 
trapping it in the cytoplasm149,178. PPP6R1 targets PPP6C to IkBe to dephosphorylate and 
protect IkBe from degradation, limiting NF-kB activity. Loss of PP6 subunits results in 
enhanced NF-kB pathway activation by TNF-a or IL-1b149,158,159,179. Other roles of PP6 in 
immune signaling include involvement in lymphocyte development and 
homeostasis159,180,181. PP6 loss impairs the development of CD4+, CD8+, and 
CD4+/CD8+ T cell populations and results in T cells more prone to differentiation and 
production of cytokines159. This likely occurs through PP6 dephosphorylation and 
regulation of the transcription factor Bcl11b, an essential factor for T-cell development181. 
In antiviral immune signaling, PPP6C in complex with WHIP and TRIM14 to 
dephosphorylate RIG-1 to promote production of type 1 interferons (IFN-1)160. 
Many large-scale proteomics studies and screens have implicated PP6 in other 
signaling pathways and cellular functions. In some cases, the relevant PP6 substrates 
have been identified, such as Argonaute 2 (AGO-2) in miRNA-mediated silencing 
pathway157 or ASK3 in osmotic stress response182. However, the precise roles or 
mechanisms of PP6 involvement in other signaling pathways are largely unknown or 
poorly understood, for example, its regulation of pre-mRNA splicing183 or the Hippo 
pathway184. The diversity of PP6 substrates and functions is unsurprising, given the 
hundreds of known substrates for PP2A. PP6 involvement in many pathways is consistent 
with its ubiquitous expression and its categorization as a “common essential” gene, or 
gene that is essential to cell growth and survival across a large panel of cell lines (739), 
in the Cancer Dependency Map Project185-187. 
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1.4.2 PPP6C Mutations in Melanoma 
PPP6C mutations are found across multiple cancer types but are most common 
in melanoma and other skin cancers, where they are thought to contribute to tumor 
development18,33,37,188. Somatic PPP6C mutations have been detected in 6-9% of 
malignant melanomas (Figure 1.2), generally co-occurring with BRAF and NRAS 
mutations18,19,33 (Figure 1.4B). The majority of these melanoma-associated mutations are 
missense mutations and often occur with loss of heterozygosity33,34,189. Of melanoma 
patient tumors with both mutational and copy number profiling data, 33 of 54 (61%) 
mutations occurred with shallow or heterozygous deletions39,40. PPP6C mutations are 
distributed throughout the primary sequence but recurrently cluster to highly conserved 
regions in or near the catalytic cleft, with R264C being the most common mutation189 
(Figure 1.4C). The clustering of PP6C mutations, and specifically the high recurrence of 
the PPP6C R264C point mutation, are suggestive of activating mutations, as seen with 
classical oncogenes. However, prior analysis of recurrent and non-recurrent PPP6C 
mutations indicate that all of them, to varying degrees, reduce catalytic activity189,190. 
Copy number loss and loss-of-function mutations indicate PPP6C likely functions as a 
tumor suppressor. Potential signaling mechanisms for known oncogenic mutations in 
melanoma have been explored and are detailed below.  
 Based on where recurrent mutations map to on the structure of the PP2A catalytic 
subunit, the mutations likely have varying consequences on PP6 activity and signaling. 
The His55 residue coordinates a critical catalytic metal ion (Figure 1.5A). Loss of this 
coordination from the recurrent H55Y mutation would be expected to render PPP6C 
catalytically inactive. Arg264 is located at an interface of the PP2A catalytic subunit and 
one of its regulatory subunits (Figure 1.5B) Instead of causing the loss of intrinsic 
phosphatase activity of the catalytic subunit, the R264C mutation may disrupt PP6 
holoenzyme assembly, possibly altering the composition of PP6 heterotrimers in cells. 
By promoting or disrupting the association of PPP6C with specific regulatory subunits, 
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mutations can alter substrate specificity and shift signaling outputs. This is the case with 
a recurrent cancer-associated mutation in a PP2A scaffolding subunit, which has been 
found to disrupt interactions with some regulatory B subunits and not others to activate 
the ERK signaling pathway191. Because PPP6C is an essential gene, complete loss of 
PPP6C function would not be tolerated by most cells. Some melanoma-associated 
mutations may spare essential functions of PP6 for survival and only disrupt tumor 
suppressive functions. 
One of the major environmental risk factors for melanoma development is 
ultraviolet radiation (UVR) from sun exposure192. Cytosine to thymidine (guanine to 
adenosine) mutations (C > T), especially in dipyrimidine contexts, are signature of UVR-
radiation-induced genetic changes. PPP6C mutations predominantly occur in sun-
exposed tumors34. The overwhelming majority of PPP6C missense mutations including 
all recurrent mutations are C > T transitions, likely attributed to mismatch repair of UV-
induced DNA damage. The R264C mutation is a cytosine to thymidine transition at a 
dipyrimidine site. While the majority of established activating MAPK pathway mutations 
(e.g., BRAFV600E, NRASQ61L/R) in melanoma do not appear to be due to direct UV-induced 
damage, PPP6C mutations are presumably generated by UVR mutagenesis and 
contribute to UVR-induced melanomagenesis. This is consistent with the belief that 
PPP6C mutations are early events in the development of melanoma189. Mutations in 
tumors before BRAFi therapy harbor a predominance of C > T transitions compared to 
mutations in progressive tumors, which have a relative reduction in C >T transitions and 
increase in other transitions101.  UVR-damage-induced PPP6C mutations potentially 
contribute to the transformation of melanocytic nevi with BRAF and NRAS mutations into 
melanoma. 
 
1.4.3 A Tumor Suppressor Role for PPP6C in Melanoma  
PPP6C is thought to be a tumor suppressor in melanoma18,19,33,37,188, yet our 
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understanding of how it modulates cancer relevant pathways is limited. Partly due to the 
lack of overtly cancer-relevant known PP6 substrates, it is unclear which substrates or 
pathways provide the molecular basis for the occurrence of melanoma-associated 
PPP6C mutations. Biochemical studies characterizing melanoma-associated PPP6C 
mutants found some mutations disrupt holoenzyme assembly and decrease PPP6C 
stability156,189,190. However, this was not the case for all mutants investigated, suggesting 
heterogeneity in functional and signaling consequences of PPP6C mutations. 
Most studies of PPP6C in melanoma have focused on its regulation of Aurora A in 
mitotic spindle assembly and chromosome segregation152,190. Melanoma-associated 
PPP6C mutations impair its ability to dephosphorylate and inactivate Aurora A, resulting 
in genomic instability, DNA damage, and micronucleation are early events contributing 
to cancer progression189,190. Expression of the PPP6C H114Y mutant, which has been 
observed twice in melanoma, in cells increases Aurora-A activity and disrupts chromatin 
and mitotic spindle organization190. The resultant mitotic spindle defects lead to 
chromosome instability and therefore DNA-damage and micronucleation. This 
chromosome instability, a hallmark and driver of cancer, suggests a role for PPP6C driver 
mutations in melanoma. Characterization of 12 other PPP6C mutants found 5 mutations 
increase Aurora A activation, 4 of which disrupts binding to the PPP6R3 subunit189. A 
subset of PPP6C mutations sensitize cells to Aurora A inhibitors independently of their 
effect on Aurora A activation. 
Work characterizing melanoma-associated PPP6C mutations is limited and 
inconsistent. Aside from the described studies of PPP6C mutants, PPP6C loss has been 
investigated for roles in tumorigenesis. Loss of PPP6C promotes oncogenic RAS driven 
tumors in mouse keratinocytes179,193 and in drosophila194. Further work is required for 
better understanding of the molecular mechanisms underlying the role of PPP6C 
mutations in melanoma. As studies point to distinct consequences of different PPP6C 
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mutations, the progress in identifying diverse functions of PP6 suggest the involvement 
of several mechanisms. 
 
1.5 Statement of Purpose 
The incidence of malignant melanoma has been rapidly increasing worldwide with 
a 270% increase over the past 30 years in the United States195. Despite important 
advances in understanding the aberrant signaling pathways driving melanoma 
tumorigenesis, current treatment options, including targeted therapies and 
immunotherapies, rarely yield complete responses. With increasing knowledge of tumor 
heterogeneity and drug resistance mechanisms, it is clear that the oncogenic signaling 
network in melanoma is highly complex and has yet to be comprehensively understood. 
A more complete understanding of these signaling networks is necessary to develop 
more efficacious and durable therapeutic strategies.  
Broadly, the purpose of this dissertation is to further advance our understanding 
of ERK MAPK signaling regulation and its deregulation in melanoma. The work described 
within this dissertation primarily focuses on MEK1/2, examining MEK regulation, 
response to MEK inhibition, and melanoma-associated mutations that alter MEK activity. 
PPP6C is identified in shRNA screens designed to identify novel modulators of MEKi 
response in BRAFV600E melanoma. Through comprehensive biochemical and cellular 
studies investigating the mechanism of PPP6C regulation of ERK signaling, PPP6C is 
established as a MEK phosphatase and therefore influences sensitivity to MAPKi. These 
findings support previous predictions of a tumor suppressor role for PPP6C in 
melanoma. Beyond the identification of a novel MEK phosphatase, melanoma-
associated PPP6C and MEK1 mutations are characterized to better understand how 
these mutations alter oncogenic signaling and potentially contribute to melanoma 
progression and MAPKi response. 
This dissertation further sheds light onto the complex regulatory mechanisms of 
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the ERK signaling network in melanoma involved in MEK and BRAF inhibitor response 
and identifies a novel role for PPP6C in a key oncogenic signaling pathway. By 
contributing to a more comprehensive understanding of the molecular mechanisms 
underlying MEK and BRAF inhibitor response, this work provides insight into the 
therapeutic limitations of targeted therapies. 
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 The RAF-MEK-ERK mitogen-activated protein kinase (MAPK) signaling cascade 
regulates essential cellular processes including cell proliferation, differentiation, and 
survival23. Deregulation of ERK signaling, typically through mutations in core pathway 
components or upstream regulators, is among the most frequent driver events in human 
cancer196. Malignant melanoma in particular is dependent upon hyperactivated ERK 
signaling. The dependence of melanomas on the ERK pathway fueled the development 
and approval of selective BRAF inhibitors (BRAFi) and MEK inhibitors (MEKi) with clinical 
efficacy in treating tumors harboring BRAFV600E mutations197. Unfortunately, responses to 
BRAFi and MEKi are almost invariably short-lived due to the development of acquired 
resistance80. While resistance to these agents can involve activation of alternative cell 
growth and survival pathways, it most commonly occurs through reactivation of the ERK 
pathway despite the continued presence of inhibitor198. Mechanisms underlying ERK 
pathway reactivation include acquisition of RAS or MEK mutations, BRAF amplification 
or alternative splicing, disruption of negative feedback regulation, and induction of 
receptor tyrosine kinases101-104. Understanding how tumor cells become resistant to 
BRAFi and MEKi can suggest additional therapeutic targets and thus contribute to the 
development of durable and more generally applicable cancer treatments. In addition, 
investigations into mechanisms of inhibitor resistance have provided insight into the 
basic wiring of the ERK pathway and how it participates in larger signaling networks.  
 Functional genetic screening strategies have been effective discovery tools for 
identifying new drug targets and biomarkers for drug response. The two technologies 
used in pooled loss-of-function screens, CRISPR and RNAi, yield robust and reliable 
results assessing large numbers of genes, even at genome-wide scale, simultaneously. 
shRNA screens were initially limited by noise due to off-target effects and inefficient gene 
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silencing. With the rapid development of CRISPR/Cas9 technology, which has a very 
low-incidence of off-target effects199,200, CRISPR-based screening has quickly gained 
popularity and become the dominant genomic screening technology, seeming to 
outperform RNAi-based screening in terms of noise and consistency201. Increasing 
redundancy in shRNA libraries and use of validated shRNA for efficient knockdown has 
improved the reproducibility of shRNA screens. Parallel comparison of CRISPR and 
shRNA screens have demonstrated similar precision in detecting essential genes 
depending on the sgRNA and shRNA libraries used201,202.  
The choice of CRISPR or shRNA systems for a functional screen should depend 
on the research question or intended application of screen results with careful 
consideration of the limitations of each technology. For example, in the case of drug 
target discovery, knockdown in shRNA screens better mimics the inhibition of a target 
by a drug. shRNA screen results are representative of hypomorphic phenotypes. The 
knockdown of genes by shRNA demonstrates the phenotypic effects of partial losses-
of-gene function depending on the knockdown efficiency of the specific shRNA hairpin. 
Another complicating factor is slow protein degradation or the discrepancy between 
mRNA transcript levels and protein levels, which would prevent loss-of-function 
phenotypes. CRISPR screen results are representative of true null phenotypes. The 
phenotypes resulting from complete knockout are not obscured by the effects from low 
levels of remaining protein expression from incomplete knockdown. This allows for high 
sensitivity from stronger phenotypes in CRISPR screens. However, this also makes it 
difficult to study the complexity of essential genes. The lethality of the knockout of these 
genes overpowers any non-survival-related functions. 
These differences in shRNA and CRISPR screens likely contribute to their ability 
to detect distinct groups of genes related to specific cellular processes202. For example, 
gene sets related to RNA polymerase and the Mediator complex, which functions as a 
transcriptional co-activator, are found in shRNA screens but not CRISPR screens, 
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presumably because shRNA knockdown depends on continued transcription of the 
shRNA unlike with sgRNAs. In the case of some other gene sets unique to one type of 
screen, the cellular functions or signaling mechanisms governing this exclusivity are 
unclear. 
Cell viability-based loss-of-function genetic screens can yield information on 
negative genetic selection and/or positive genetic selection in response to a given 
selection pressure such as an inhibitor. Negatively selected genes identify genes that 
when silenced gives cells a disadvantage in the conditions being studied. When 
interpreting screen results, the shRNA or sgRNA sequences targeting these genes are 
depleted from the cell population over the course of the screen. Negative selection is 
used to identify genes essential for survival or proliferation in the context of a given 
selection pressure, providing insight into synthetic lethal dependencies and context-
specific genetic vulnerabilities. Genes identified under negative selection from drug 
treatment represent potential drug targets for combinatorial therapeutic strategies. 
Because negatively selected genes also include essential genes, understanding which 
genes are specific to the added selection pressure requires comparison to appropriate 
control conditions. Positively selected genes identify genes that when silenced gives 
cells a growth or survival advantage. The shRNA or sgRNA sequences targeting these 
genes are enriched in the cell population over the course of the screen These genes 
confer sensitivity to the selection pressure when expressed and therefore provide insight 
into potential mechanisms of drug resistance. 
The emergence of BRAFi resistance in melanoma has prompted several genetic 
screens investigating BRAFi susceptibility. When comparing results from similar 
screens, whether they use the same inhibitor or the same cell line, there is often a 
divergence in genes-of-interest outside of essential genes due to the many variables 
involved in these large-scale screens, including context dependency of genetic 
interactions, library size and complexity, and inhibitor treatment conditions, just to name 
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a few202. COT, CDK6, BOP1, HAT1, and CUL3 have all been identified as mediators of 
BRAFi resistance in BRAFV600E melanoma in different screens139,141,144,146, demonstrating 
that similar screens are able to identify unique physiologically relevant hits and produce 
non-redundant information.  
BRAFi and MEKi combinations are the current standard of care for BRAFV600E 
melanoma but are limited by the onset of inhibitor resistance. While both BRAFi and MEKi 
block the same pathway, mechanisms involved in BRAFi and MEKi response and 
resistance in cells may differ as suggested by the longer progression-free survival with 
combination therapy and the additional increase in response rate to BRAFi upon 
acquiring MEKi resistance in BRAF melanoma patients in studies investigating treatment 
schedules203. MEK and BRAFV600E are individually regulated and exhibit different 
susceptibility to ERK pathway negative feedback and therefore can be limited by target-
specific resistance in addition to pathway-specific resistance. 
Functional genetic screens with MEKi have focused on RAS-driven cancers 
because of the limited efficacy of MAPKi in RAS mutant cancers204-207. Finding synthetic 
lethal interactions in the context of inhibited RAS effector pathways, such as the ERK 
signaling pathway, for combination therapeutic development is the major approach to 
treat the MAPKi-resistant majority population of RAS mutant cancers. With the FDA-
approved use of MEKi in BRAFV600E melanoma, genetic screens investigating MEKi 
response in BRAFV600E melanoma can provide a better understanding of the specific 
genetic vulnerabilities of BRAFV600E melanoma in MEKi response. 
 
2.1.1 MEKi Sensitivity Screen Design 
To identify genes involved in modulating the response to MEKi, we performed a 
pooled shRNA screen in two BRAFV600E melanoma cell lines (Figure 2.1). We used a 
custom-made lentiviral library of 7,649 shRNAs targeting 817 genes encoding annotated 
protein and lipid kinases and phosphatases. This library targets genes encoding 
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theoretically druggable proteins. These proteins are able to bind drug-like molecules 
and in the case of many kinases have specific chemical inhibitors readily available for 
studies exploring combinatorial effects with MEKi. After transduction with the shRNA 
library, we harvested a portion of the cells for a start time reference sample (T0) and 
divided the remaining cells into 5 populations, which were subsequently treated with 
either vehicle control or one of two concentrations of the clinical MEKi trametinib and 
selumetinib. MEKi concentrations were chosen to flank the approximate IC50 for inhibition 
of cell growth. Cells were propagated through 10 population doublings (T1-T10). The 
change in abundance of each shRNA under each growth condition was then determined 
by next-generation sequencing (Illumina HiSeq) following PCR amplification from 
genomic DNA preparations of cells collected at T0 and T10. We used RNAi gene 
enrichment ranking (RIGER) analysis208 to rank genes based on the depletion or 
enrichment of their shRNAs in the screen.  
“Depleted genes”, which are genes whose hairpins are depleted from MEKi-
treated cell populations over the course of the screen, will also be referred to as “drop-
out hits”. These negatively selected genes sensitize cells to MEK inhibition when 
knocked down. Not only do these drop-out hits offer insight into the signaling involved in 
MEKi response, they also represent potential drug targets for combinatorial therapy with 
MEKi. “Enriched genes”, which are genes whose hairpins are enriched in MEKi-treated 
cell populations, will also be referred to as “drop-in hits”. Downregulation or loss of these 
positively selected genes render the cells less sensitive to MEK inhibition. Similar to 
drop-out hits, these genes provide insight into MEKi response signaling but can also 
suggest potential drug resistance mechanisms and biomarkers for patient selection. 
 
2.2 Results 
2.2.1 501mel screens  
Studies have described a largely cytostatic effect or growth delay with MEKi in 
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melanoma, both in cell culture and xenografts199,209-211. Tumor growth inhibition but not 
tumor regression in mouse xenograft models199,211 translates to mostly stable disease 
and some partial responses to trametinib monotherapy in patients for improved 
progression-free and overall survival76,212. We selected 501mel cells, a BRAFV600E 
melanoma cell line that exhibits cytostatic responses to MEKi, hoping to gain insight into 
the signaling limiting MEK inhibition to cytostatic effects as opposed to cytotoxic effects 
in melanoma. High and low MEKi concentrations were selected to flank the IC50 for 
inhibition of cell growth (1 nM trametinib, 3.3 nM trametinib, 33 nM selumetinib, and 100 
nM selumetinib). To assess the performance of both screen replicates, we evaluated the 
mean coverage of mapped reads per each shRNA which was 12,551 in the first replicate 
and 15,364 in the second replicate. This is well above the recommended read depth of 
1,000 reads per shRNA for accurate hit identification.  As expected for a BRAFV600E cell 
line, all 6 hairpins targeting BRAF in the shRNA library are depleted from all populations 
over time, providing an internal control for the screen (Figure 2.2). 
To identify enriched genes of interest, I selected the top 50 ranking genes (top 
6.1%) from RIGER analysis of each MEKi condition and removed overlapping top-
ranking genes from the no drug condition. The overlap of enriched genes between MEKi 
conditions for each screen replicate was used to generate a list of drop-in genes of 
interest (Figure 2.3). Of these MEKi specific hits, Protein Phosphatase 6 Catalytic subunit 
(PPP6C), is the top ranked gene in 5 of 8 MEKi conditions across the two screen 
replicates and scored within the top 20 genes in all drug conditions (Figure 2.4). The 
hairpins targeting PPP6C are the most consistently enriched in the presence of MEKi 
and are generally depleted from the untreated culture (Figure 2.3, 2.5). These results 
suggest that PPP6C is required both for optimal cell growth and for a maximal cytostatic 
response to MEKi. Other potential drop-in genes of interest include Protein Phosphatase 
1 Regulatory Subunit 12A (PPP1R12A or MYPT1), Phospholipid Phosphatase Related 3 





Figure 2.1 Schematic of the pooled shRNA MEKi sensitivity screen. 
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Figure 2.2 BRAF shRNA hairpins are depleted from all cell populations  
Changes in all shRNA hairpins shown as log2(T10/T0) from most depleted to most enriched 
for each drug condition. Bars representing shRNA hairpins targeting BRAF are shown in 




Figure 2.3 Top enriched genes for each drug condition from two replicates of the 501mel screen.  
(A) Venn diagrams of top 50 enriched genes for each drug condition.  
(B) The most consistently enriched genes across MEKi conditions. Colored boxes indicate 
the genes ranked in the top 50 enriched genes by RIGER for that drug condition not 




Figure 2.4 501mel Screen Rankings of Drop-in hits 
The top 20 ranked enriched genes for each condition for 501mel screen replicates. 





Figure 2.5 PPP6C shRNA hairpins are enriched in MEKi conditions 
(A) Rankings for each of the 6 PPP6C hairpins out of the 7,649 shRNAs in the library are 
listed for each drug condition.  
(B) Changes in all shRNA hairpins shown as log2(T10/T0) from most depleted to most enriched 
for each drug condition. Bars representing shRNA hairpins targeting PPP6C are shown 




Figure 2.6 Top depleted genes for each drug condition from two replicates of the 501mel screen. 
(A) Venn diagrams of top 50 depleted genes for each drug condition.  
(B) The most consistently depleted genes across MEKi conditions. Colored boxes indicate 
the genes ranked in the top 50 depleted genes by RIGER for that drug condition not 
found in the DMSO control condition.  
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ranked as top drop-in hits in ³ 5 of the 8 MEKi conditions (Figure 2.3, 2.4). 
No genes are top drop-out hits in all 8 MEKi conditions across both screen 
replicates (Figure 2.6A). Of note, CRAF (RAF1) is ranked as a top gene in 3 MEKi 
conditions (Figure 2.6B). This is consistent with its role activating the ERK signaling 
pathway through the phosphorylation of MEK. CRAF upregulation is a known MAPKi 
resistance mechanism (Figure 1.3). ITK, DSTYK, PTPN9, and CHEK1 are top drop-out 
hits in ³ 5 of the 8 MEKi conditions (Figure 2.6B). ITK, interleukin-2-inducible T-cell 
kinase, is a top ranked gene in the 2 low MEKi concentrations (1nM trametinib and 33nM 
selumetinib) of the first screen replicate and all 4 MEKi conditions of the second screen 
replicate. 
 
2.2.2 Yugen8 Screens  
 We selected a patient derived BRAFV600E melanoma cell line, Yugen8, for our next 
set of MEKi screens. Compared to 501mel cells, Yugen8 cells are more sensitive to MEKi 
and exhibit cytotoxic responses. The MEKi IC50 flanking concentrations selected for 
these screens were 0.03 nM trametinib, 0.1 nM trametinib, 8 nM selumetinib, and 25 nM 
selumetinib. The mean coverage of mapped reads per each shRNA was 11,376 in the 
first replicate and 21,405 in the second replicate.  
The top ranked genes in the Yugen8 screens were not as consistent between the 
two screen replicates as they were in the 501mel screens (Figures 2.7, 2.8). Of the drop-
in hits, Kinase Suppressor of Ras1 (KSR1) was the most consistent, ranking in the top 
50 genes in all 4 MEKi conditions of one screen replicate (Figure 2.7B). However, it is 
not ranked in any MEKi conditions in the other replicate. Other drop-in hits only rank in 
3 or fewer of the 8 MEKi conditions. Of the drop-out hits, Diacylglycerol Kinase Epsilon 
(DGKE) and Nuclear Receptor Binding Protein 1 (NRBP1) are both ranked as top drop-
in hits in 5 of the 8 MEKi conditions (Figure 2.8B). Six other genes are top ranked in 4 of 




Figure 2.7 Top enriched genes for each drug condition from two replicates of the Yugen8 screen.  
(A) Venn diagrams of top 50 enriched genes for each drug condition.  
(B) The most consistently enriched genes across MEKi conditions. Colored boxes indicate 
the genes ranked in the top 50 enriched genes by RIGER for that drug condition not 




Figure 2.8 Top depleted genes for each drug condition from two replicates of the Yugen8 screen.  
(A) Venn diagrams of top 50 depleted genes for each drug condition.  
(B) The most consistently depleted genes across MEKi conditions. Colored boxes indicate 
the genes ranked in the top 50 depleted genes by RIGER for that drug condition not 




Figure 2.9 Top ranked genes from all screens.  
(A) The most consistent drop-in genes across MEKi conditions. Colored circles indicate 
the genes ranked in the top 50 enriched genes by RIGER for that drug condition not 
found in the DMSO control condition.  
(B) The most consistent drop-out genes across MEKi conditions. Colored circles indicate 
the genes ranked in the top 50 depleted genes by RIGER for that drug condition not 
found in the DMSO control condition.  
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2.2.3 Validation of Screen Hits  
PPP6C Validation 
The most consistent hit among shRNA screens with the 501mel cell line and the 
patient-derived Yugen8 cell line is PPP6C (Figure 2.9A). PPP6C ranks as a top gene in 
10 MEKi conditions of 16 total MEKi conditions across both replicate screens of both cell 
lines. 
To confirm a role for PPP6C as a factor modulating sensitivity to MEKi, 501mel 
cells were transduced with non-targeting control shRNA (shCTRL) or one of two 
independent shRNAs (shPPP6C-1, shPPP6C-2) that efficiently decrease PPP6C 
expression. PPP6C knockdown caused modest but consistent rightward shifts to MEKi 
dose responses curves, increasing IC50 values for growth inhibition by trametinib and 
selumetinib (Figure 2.10A). In clonogenic assays, cells transduced with control shRNA 
exhibited dose-dependent growth inhibition by both MEKi as anticipated (Figure 2.10B). 
PPP6C knockdown alone substantially decreased cell growth, yet this growth defect was 
partially reversed in the presence of low concentrations of MEKi. To further verify that 
PPP6C regulates ERK signaling, we generated clonal PPP6C knockout 501mel lines by 
CRISPR/Cas9-mediated gene disruption (Figure 2.11). Notably, we were unable to 
expand PPP6C-/- clones unless we supplemented the growth media with a low 
concentration of the MEKi trametinib. PPP6C knockout clones also exhibited decreased 
sensitivity to MEKi but with more pronounced rightward shifts to MEKi dose responses 
curves (Figure 2.12A). Also consistent with PPP6C knockdown, PPP6C knockout 
decreased cell growth in clonogenic assays which is reversible with similar as well as 
higher concentrations of trametinib (Figure 2.12B). These observations verify that PPP6C 
silencing renders 501mel cells less sensitive to the cytostatic effects of MEKi.  
The results in these validation studies are consistent with the behavior of PPP6C 
shRNA hairpins in the 501mel screens, demonstrating the capability of these shRNA 
screens to identify a verifiable positive modulator of MEKi response. Additional work  
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Figure 2.10 shRNA knockdown of PPP6C reduces cell growth and MEKi sensitivity 
(A) 501mel cell lines stably expressing control shRNA (shCTRL) or PPP6C-targeting shRNA 
(shPPP6C-1, shPPP6C-2) were treated for 72 hours with increasing concentrations of 
trametinib or selumetinib. Cell viability was detected by alamarBlue reagent and 
normalized to a no drug control for each cell line. Dose response curves for shCTRL 
(black), shPPP6C-1 (dark blue), and shPPP6C-2 (light blue) are shown. MEKi IC50 values 
and 95% confidence intervals are listed in the table. 
(B) shCTRL, shPPP6C-1, and shPPP6C-2 expressing 501mel cells were cultured in DMSO 
or the indicated concentration of trametinib or selumetinib for 2 weeks in colony forming 
assays. Colonies were stained with crystal violet. Clonogenic growth was analyzed by 
ColonyArea in ImageJ. Quantification was normalized to PPP6C+/+, no drug. Mean values 




Figure 2.11 PPP6C CRISPR/Cas9 knockout cell lines  
Sanger sequencing chromatograms for PPP6C+/+ and PPP6C-/- clonal 501mel cell lines 
generated by CRISPR/Cas9. Immunoblot confirming PPP6C loss in PPP6C-/- 501mel cell 




Figure 2.12 CRISPR/Cas-9 mediated knockout of PPP6C reduces cell growth and MEKi 
sensitivity 
(A) PPP6C+/+ and PPP6C-/- 501mel cells were treated for 72 hours with increasing 
concentrations of trametinib or selumetinib. Cell viability was detected by alamarBlue 
reagent and normalized to a no drug control for each cell line. MEKi IC50 values and 95% 
confidence intervals are listed in the table. 
(B) PPP6C+/+ and PPP6C-/- 501mel cells were cultured in media containing DMSO or the 
indicated concentration of trametinib for 2 weeks in colony forming assays. Colonies 
were stained with crystal violet. Clonogenic growth was analyzed by ColonyArea in 




Figure 2.13 ITK inhibition sensitizes cells to MEKi 
501mel cells were treated for 72 hours with increasing concentrations of trametinib with 
(blue) or without (black) 1uM ibrutinib. Cell viability was detected by alamarBlue reagent 
and normalized to a no drug control for each cell line. IC50 values and 95% confidence 
intervals are listed in the table, n = 2. 
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describing a role for PPP6C in ERK signaling and MAPKi response is reported in Chapter 
3 of this dissertation. 
 
ITK Validation 
ITK is one of 3 genes that are top enriched genes in 8 MEKi conditions across all 
four screens (Figure 2.9B). ITK is normally considered an immune cell-specific protein 
but has been found to be aberrantly expressed in metastatic melanoma213. In T-cell 
receptor (TCR) signaling, ITK is a downstream effector of TCR stimulation and mediates 
the activation of ERK214,215. The identification of ITK as a drop-out hit suggests inhibition 
of ITK may potentiate the cytostatic or cytotoxic effects of MEK inhibition in cells. Ibrutinib 
is a clinical inhibitor of BTK, but also potently inhibits ITK and other tyrosine kinases. To 
investigate ITK as a sensitizer to MEK inhibition, 501mel cells were treated with Ibrutinib 
in combination with trametinib in pilot assays. The addition of 1uM ibrutinib shifts 
trametinib dose response curves to the left, decreasing the IC50 value by 3-fold for growth 
inhibition by trametinib (Figure 2.13). Ibrutinib made cells more sensitive to the cytostatic 
effects of trametinib, but it did not sensitize them to potential cytotoxic effects in 501mel 
cells.  The sensitization to MEK inhibition may be mediated by the inhibition of Ibrutinib’s 
many targets Additional work is necessary to investigate and optimize MEKi and ITK 
inhibitor concentrations for use in combination as well as to elucidate a specific 
mechanism for this effect. These preliminary experiments confirm ITK loss or inhibition 
promotes MEKi response as seen in our screens. 
 
2.3 Discussion 
We demonstrate the identification of modulators of MEKi sensitivity using a loss-
of-function screening strategy in BRAFV600E melanoma cells. Our screens generated an 
abundance of information including insight into potential drug targets, previously 
unappreciated signaling factors regulating the ERK signaling pathway, and candidate 
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genes identified in similar functional genetic screens investigating MAPKi response.  
The use of the top 50 ranked genes to select hits only considers the top 6.1% of 
genes targeted by our shRNA library. This cutoff is stringent and likely results in the 
exclusion or lower ranking of relevant genes. Although a less conservative cutoff may 
allow for the identification of more candidate genes, we were able to validate the top 
drop-in and drop-out genes identified in our screens.  
PPP6C is a clear gene of interest, given its top rankings in the majority of MEKi 
concentrations. In validation studies, PPP6C knockdown with shRNA and knockout with 
CRISPR/Cas9-mediated gene disruption decreased sensitivity of 501mel cells to MEKi. 
PPP6C knockdown and knockout cells exhibit impaired growth and proliferation 
compared to control cells which is partially reversed with MEKi treatment. This behavior 
mirrors what we observed in our screens where PPP6C hairpins were depleted from drug 
free cell populations but enriched in MEKi-treated cell populations. Our comprehensive 
investigation of PPP6C in ERK signaling in melanoma is described in the next chapter. 
ITK, the top drop-out hit, is known to activate the ERK signaling pathway 
specifically in TCR signaling but has not been investigated in other signaling contexts. 
The expression of ITK in benign melanocytic lineage cells is low as expected but is 
unexpectedly highly elevated in metastatic melanoma tissue samples213. ITK inhibition in 
a BRAFV600E melanoma mouse model and a panel of melanoma cell lines, decreases cell 
proliferation and migration. In a T lymphocyte cell line, treatment with several ITK 
inhibitors inhibit MEK phosphorylation to varying degrees216. We demonstrate combining 
a ITK inhibitor with a MEKi has a stronger cytostatic effect in BRAFV600E melanoma cells 
compared to MEKi alone. Our findings in combination with other indications of ITK 
involvement in ERK signaling or melanoma progression support the additional 
exploration of ITK in these roles. 
 Cursory review of other top ranked genes suggests potentially interesting 
involvement of these candidate genes in MAPKi response or melanoma signaling. KSR1, 
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the top enriched gene in the Yugen8 screens (Figure 2.7B), is an interesting hit 
considering its role as a scaffold for the ERK signaling pathway. KSR1 enhances ERK1/2 
signaling activation by binding ERK pathway components and regulating the efficiency 
of their interactions217. Recently solved crystal structures and functional studies show 
trametinib binds MEK-KSR complexes promoting MEK engagement of KSR1/2 and 
disrupting MEK activating interactions with RAFs218. This unexpected involvement of KSR 
in the mechanism of action for MEKi is supported by our identification of KSR1 as a drop-
in hit. The loss of KSR1-MEK complexes with KSR1 knockdown likely hampers the ability 
of MEKi to bind and inhibit MEK. 
A mutation in DSTYK, a top drop-out hit in our screens (Figure 2.9B), has been 
shown to activate ERK signaling to promote cell migration and invasion, which is 
inhibited with MEKi treatment219. DSTYK is upregulated in metastatic melanoma cell 
lines220 and metastatic colorectal cancer tumor samples221. DSTYK loss inhibits FGF-
stimulated ERK phosphorylation in human embryonic kidney cells (HEK)222. This is all in 
line with a potential role for DSTYK in positively regulating ERK signaling or inhibiting 
MAPKi response.  
  INPP4B, a top ranked drop-in gene (Figure 2.9A), has been described to have 
tumor suppressor functions in breast cancer and melanoma through its role as a 
negative regulator of PI3K-AKT signaling223-225. INPP4B expression is reduced in 
melanoma tumor samples compared to nevi and expression levels are only moderately 
correlate with AKT activation. The impact of INPP4B on the ERK signaling pathway or 
MAPKi response has not been explored, but a role for INPP4B in regulating both PI3K-
AKT signaling and ERK signaling is possible either independently or through crosstalk 
between the pathways.  
These speculations for possible roles for these genes-of-interest in modulating 
MAPKi sensitivity or melanoma progression are premature given the need for additional 
studies to validate their identification in our screens. The identification of these genes 
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may be due to off-target effects of shRNAs or other variables effecting the accuracy of 
these screens. However, our follow-up investigation into PPP6C and its involvement in 
ERK signaling establish PPP6C as a previously unknown MEK phosphatase (Chapter 3).  
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CHAPTER 3: PPP6C REGULATION OF ERK SIGNALING IN MELANOMA 
3.1 Introduction 
Because proper control of the ERK pathway is important to normal physiology, 
the core cascade is positioned within a complex network involving extensive feedback 
and crosstalk regulation23. By counteracting regulatory phosphorylation events, protein 
phosphatases play key roles in controlling the magnitude and duration of ERK signaling, 
and their dysregulation can contribute to disease and influence inhibitor sensitivity. For 
example, ERK signaling induces expression of dual-specificity MAPK phosphatases 
(DUSPs), which dephosphorylate and inactivate ERK226. Disruption of this negative 
feedback loop through deletion or downregulation of ERK-selective DUSPs has been 
reported in some tumors and is associated with more advanced disease and poor 
patient prognosis227-230. Protein phosphatases also have important roles in positively 
regulating ERK signaling. For example, the tyrosine phosphatase SHP2 is important for 
relaying signals from receptor tyrosine kinases to RAS GTPases, and SHP2 inhibitors are 
currently in development as cancer therapeutics231. In addition, the MRAS-SHOC2-PP1 
complex dephosphorylates an inhibitory site on RAF and mediates ERK pathway 
reactivation induced by MEKi in KRAS mutant pancreatic and lung cancers206,232. 
Germline gain-of-function mutations in SHP2, MRAS and SHOC2 are a cause of 
developmental disorders termed RASopathies that are characterized by hyperactive 
ERK signaling233. Protein phosphatase 2A (PP2A) can promote ERK signaling by 
dephosphorylating inhibitory feedback phosphorylation sites on RAF and the ERK 
pathway scaffold KSR1234. While these phosphatases regulating RAS, RAF and ERK 
have established roles in normal and pathological signaling, less is known about 
phosphatases regulating MEK, the central component of the cascade. PP2A was initially 
identified as a MEK phosphatase in vitro and in non-transformed monkey kidney CV-1 
cells235,236. However, other studies have suggested that PP2A restrains oncogenic MAPK 
signaling primarily through direct dephosphorylation of ERK237.  
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We identified PPP6C as a gene modulating the response of BRAFV600E melanoma 
cell lines to MEKi in shRNA screens investigating MEKi sensitivity (Chapter 2, Figure 
2.9A). Loss of PPP6C appears to decrease sensitivity to the MEKi trametinib and 
selumetinib. Presumptive loss-of-function melanoma-associated mutations in PPP6C has 
piqued interest in PPP6C potentially having a key role in melanoma. However, the 
specific substrates of PPP6C that contribute to melanoma have not been fully elucidated, 
although hyperphosphorylation of Aurora A due to PPP6C loss been proposed as an 
early event in melanoma formation189,190. Interestingly, PPP6C has not previously been 
identified as a regulator of ERK signaling. In this chapter, we establish PPP6C as a MEK 
phosphatase and negative regulator of ERK signaling. We explore the involvement of 
PPP6C in melanoma signaling and MAPKi response and how melanoma-associated 
mutations may disrupt these functions. 
 
3.2 Results 
3.2.1 PPP6C negatively regulates ERK signaling  
In our validation studies (Chapter 2.2.3), PPP6C knockdown and knockout not 
only decreases sensitivity to the MEKi, but also decreases overall cell growth in the 
absence of MEKi (Figure 2.10B, 2.12B). We suspected that loss of PPP6C led to ERK 
pathway hyperactivation, as this phenomenon can underlie inhibitor resistance and 
cause growth suppression238,239. Indeed, we observed that silencing of PPP6C in 501mel 
cells elevated the levels of activating phosphorylation of ERK1/2 and MEK1/2 (Figure 
3.1A). Cells expressing shPPP6C required higher concentrations of inhibitor to reduce 
MEK and ERK phosphorylation to levels seen in control cells (Figure 3.1B), likely 
explaining why PPP6C knockdown decreases sensitivity to MEKi. Likewise, low 
concentrations of MEKi attenuated hyperactivation of ERK signaling that is presumably 
toxic to these cells, explaining why decreasing PPP6C expression reduces growth. 
Furthermore, the ability of low concentrations of MEKi to rescue growth suggests that 
PPP6C is required for optimal growth of 501mel cells largely because it restrains ERK  
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Figure 3.1 PPP6C negatively regulates ERK signaling and promotes MEKi response 
(A) 501mel cells stably expressing shCTRL, shPPP6C-1, and shPPP6C-2 were lysed and 
assessed by immunoblot for levels of phosphorylated and total MEK and ERK. 
Quantification of Phospho/Total MEK and ERK was normalized to shCTRL. Data are 
represented as mean ± SD, n = 4. 
(B) shCTRL and shPPP6C expressing 501mel cells were treated with the indicated 
concentrations of trametinib for 1 hour and lysed. Phosphorylated and total levels of MEK 




Figure 3.2 PPP6C negatively regulates ERK signaling and promotes cell proliferation 
(A) PPP6C-/- 501mel cell lines were established by CRISPR/Cas9. PPP6C+/+ and PPP6C-/- cell 
lines were lysed and assessed by immunoblot for levels of phosphorylated and total MEK 
and ERK. Quantification of Phospho/Total MEK and ERK was normalized to PPP6C+/+. 
Data are represented as mean ± SD, n = 3. 
(B) PPP6C+/+ and PPP6C-/- 501mel cells stably expressing WT PPP6C, phosphatase inactive 
PPP6CD84N (PD), or GFP (-) as a control were lysed and assessed by immunoblot for 
phosphorylated and total MEK and ERK.  
(C) Cell proliferation was measured by cell counting for PPP6C+/+ and PPP6C-/- cells 
expressing GFP, WT PPP6C, or PD PPP6C. Mean values ± SD are shown, n = 2. 
(D) shCTRL, shPPP6C-1, and shPPP6C-2 expressing 501mel cells and PPP6C+/+ and PPP6C-
/-  501mel cells were lysed and assessed by immunoblot for full length and cleaved 
Caspase-3 and PARP. Representative blots shown, n = 3 
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signaling. The complete loss of PPP6C in the PPP6C-/- clonal cell lines described in 2.2.3 
(Figure 2.11) resulted in an even more pronounced increase in MEK and ERK 
phosphorylation than seen with partial loss of PPP6C via shRNA (Figure 3.2A). Re-
expression of wild-type (WT) PPP6C, but not a phosphatase inactive mutant (D84N, PD) 
in these cells reversed ERK hyperactivation (Figure 3.2B), indicating that negative 
regulation of ERK signaling requires PPP6C phosphatase activity. Consistent with this 
observation, re-expression of WT, but not PD, PPP6C rescued the growth defect seen in 
PPP6C knockout cells (Figure 3.2C). PPP6C loss did not appear to induce apoptosis in 
501mel cell lines as judged by levels of caspase-3 and PARP cleavage, suggesting that 
it causes slow growth rather than cell death (Fig 3.2D).  
To determine whether PPP6C acts as a general regulator of ERK signaling outside 
of the cell line used for our screen, we examined the effect of PPP6C knockdown in a 
panel of cell lines of varying genotype and lineage (Figure 3.3, 3.4). We found that 
silencing PPP6C expression led to MEK hyperphosphorylation in each of five additional 
BRAFV600 mutant melanoma cell lines tested, including Yugen8 cells from our screens 
described in Chapter 2 and YURIF cells heterozygous for a PPP6CS270L mutation. Among 
four NRASQ61 mutant melanoma cell lines, all but one (YUGASP) exhibited increased 
MEK phosphorylation upon PPP6C knockdown. We observed the same phenomenon 
with MEL-ST, a non-transformed immortalized melanocyte cell line. Additionally, in three 
colon carcinoma cell lines with BRAF or RAS mutations, we also observed increased 
MEK phosphorylation with PPP6C loss. We note that the impact of PPP6C knockdown 
on the level of ERK phosphorylation across this panel of cell lines was more variable, 
suggesting that feedback mechanisms acting directly on ERK may blunt regulation by 
PPP6C.  The osteosarcoma cell line U2OS, which does not harbor BRAF or RAS 
mutations, and KRAS mutant A549 lung adenocarcinoma cells did not display consistent 
increases in phospho-MEK levels upon PPP6C knockdown. Overall, the large majority of 
cell lines examined displayed PPP6C regulation of ERK signaling.  
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We further examined a role for PPP6C as a regulator of ERK signaling by analyzing 
data from the Cancer Dependency Map Project185-187, which compiles the results of 
genome-wide CRISPR/Cas9 screens across a large panel (739) of cell lines. PPP6C is 
categorized as a common essential gene with an average CERES gene dependency 
score of -1.00 ± 0.28, where a more negative score indicates a larger effect on cell 
growth or survival187.  Notably, in skin cancer cell lines, the mean CERES score for PPP6C 
is -1.16 ± 0.31, indicating these cell lines are in general more dependent on PPP6C. 
Among skin cancer cell lines, those with BRAF hotspot mutations were significantly more 
dependent on PPP6C than those that are wild-type for BRAF (Figure 3.5A). Taken 
together with our data in 501mel cells, these data suggest that cells characterized by 
hyperactive ERK signaling are more sensitive to loss of PPP6C. 
 We also compared the dependency of skin cancer cell lines on PPP6C and core 
components of the ERK signaling pathway by examining pairwise correlations between 
genes. In these data, co-dependency between two genes across cell lines can indicate 
that they participate in a common pathway240,241. Dependency on PPP6C significantly 
correlates with dependency on BRAF, MAP2K1 (encoding MEK1), and MAPK1 
(encoding ERK2) (Figures 3.5B-F). Strikingly, strongest co-dependency with PPP6C was 
found among negative regulators of the pathway, the ERK selective dual-specificity 
protein phosphatases (DUSP4, DUSP5, DUSP6, and DUSP7). Consistent with a key role 
for PPP6C in dephosphorylating Aurora A152,190, PPP6C dependency negatively 
correlated with that of AURKA among the full set of cell lines across all lineages 
(Pearson’s correlation coefficient = -0.216, p = 1.40 x 10-9) (Figure 3.5G). However, this 
correlation was not significant in skin cancer cell lines (p = 0.44) (Figure 3.5H), 
suggesting that regulation of Aurora A is not the primary determinant of PPP6C 
dependency in these cells. Overall, these correlations suggest that in skin cancer cell 
lines, dependency on PPP6C is associated with its role as a regulator of ERK signaling.  
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To examine whether PPP6C might modulate ERK signaling in human melanoma, 
we analyzed reverse-phase protein array and RNA-seq data collected across a panel of 
tumors from The Cancer Genome Atlas. We observed a significant correlation between 
PPP6C mRNA expression and levels of both phospho-MEK and phospho-ERK among 
tumor specimens (Figure 3.6A, B). However, the extent of ERK pathway activation was 
not significantly higher in tumors harboring recurrent or truncating PPP6C mutations (Fig 
3.6C, D). These data suggest that MEK phosphorylation in melanoma tumors may be 
more strongly influenced by PPP6C levels than by its mutation.  
 
3.2.2 PPP6C regulates ERK signaling via MEK1/2 
Hyperphosphorylation of MEK observed with PPP6C loss suggests PPP6C 
regulates ERK signaling either at the level of MEK or upstream of MEK. To determine 
which component of the ERK signaling cascade is regulated by PPP6C, we initially 
investigated the RAF kinases directly upstream of MEK. In BRAFV600E mutant melanoma, 
oncogenic signaling is driven primarily by mutant BRAF, with little contribution from the 
other RAF isoforms ARAF and CRAF42. However, in settings of MEKi/BRAFi resistance, 
ERK pathway reactivation can occur in a manner dependent on CRAF, for example by 
induction of upstream receptor tyrosine kinases115,242,243 (Figure 1.3). To determine if 
increased MEK phosphorylation observed with PPP6C loss is due to compensation by 
ARAF or CRAF, we silenced each of the RAF isoforms by siRNA in combination with 
shRNA knockdown of PPP6C in 501mel cells (Figure 3.7A, B). In both the shCTRL and 
shPPP6C cells, only BRAF knockdown decreased MEK phosphorylation, while silencing 
ARAF and CRAF alone or in combination (Figure 3.7C) did not. Thus, in the context of 
PPP6C loss, BRAF remains the principal activator of MEK in 501mel cells. We note that 
in cells harboring RAS mutations, other RAF isoforms such as CRAF likely have a 




Figure 3.3 PPP6C regulation of ERK signaling is prominent in ERK pathway-driven cancer cells 
The indicated cell lines were transduced to stably express control (shCTRL) or PPP6C-
targeting (shPPP6C-1 or PPP6C-2) shRNAs. Cells were lysed and assessed by 
immunoblot for levels of phosphorylated and total MEK and ERK. Quantification is shown 




Figure 3.4 PPP6C regulation of ERK signaling in cancer cell lines  
Quantification of the relative levels of Phospho/Total MEK and ERK from Figure 3.4 was 
normalized to shCTRL for each cell line. Data are represented as mean + SD, n ≥ 2. 
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Figure 3.5 PPP6C dependency and ERK pathway dependency 
(A) PPP6C CERES scores for skin cancer cell lines with WT BRAF or hotspot BRAF mutations 
from the Cancer Dependency Map Project. Cell lines harboring non-recurrent BRAF 
variants of unknown significance were excluded. Data are represented as mean ± SD. 
***p < 0.0005, Welch’s t test.  
(B) Heatmaps depicting CERES scores of PPP6C, ERK selective DUSPs, and ERK MAPK 
cascade components in skin cancer cell lines using data from Cancer Dependency Map 
Project. Pearson’s correlation coefficients and p-values from linear regression analysis of 
each gene with PPP6C in the DepMap portal are listed. 
   (C-G)  CERES scores for PPP6C (x-axis) plotted against CERES scores for (C) DUSP6,  
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(D) BRAF, (E) MEK1, (F) ERK2, and (G) Aurora A (y-axis). CERES scores are for all skin 
cancer cell lines from the Cancer Dependency MAP Project. Pearson’s correlation 
coefficients (r) and associated p-values from linear regression analysis are indicated. 
(H) CERES scores for PPP6C (x-axis) plotted against CERES scores for Aurora A (y-axis). 
CERES scores are for all cancer cell lines from the Cancer Dependency MAP Project. 
Pearson’s correlation coefficient (r) and associated p-value from linear regression 




Figure 3.6 PPP6C mutational status and ERK pathway activation 
(A) PPP6C RNA-seq mRNA expression level plotted against MEK1 phosphorylation levels 
(MEK1 pSer221, pThr217) for TCGA tumor samples in cBioPortal. Correlation coefficients 
and associated p-values from linear regression analyses are indicated. 
(B)  PPP6C mRNA levels plotted against ERK2 phosphorylation levels (ERK2 pThr202, 
pTyr204) for TCGA tumor samples as in (A). 
(C) MEK phosphorylation levels (MEK1 pSer221, pThr217). Data were obtained from 
cBioPortal and are represented as mean ± SD. 
(D) ERK phosphorylation levels (ERK2 pThr202, pTyr204) for TCGA tumor samples with WT 




We next considered whether loss of PPP6C leads to increased BRAF activity. To 
do so, we immunoprecipitated endogenous BRAF from shCTRL cells and shPPP6C cells 
and examined its vemurafenib-sensitive kinase activity on MEK1 in vitro.  We found that 
BRAF isolated from both shCTRL and shPPP6C cells phosphorylated MEK1 at similar 
rates (Figure 3.8A), indicating PPP6C does not regulate BRAF activity.  While we did not 
observe changes in RAF expression levels with PPP6C loss (Figures 3.7A), we did note 
upward electrophoretic mobility shifts suggestive of a change in the phosphorylation 
states of BRAF and CRAF that could have a regulatory role (Figure 3.8B). We found 
however that treatment of cells with MEKi or BRAFi caused the multiple BRAF species to 
collapse into a lower, presumably less phosphorylated species (Figure 3.8B, C). The 
increased RAF phosphorylation observed in shPPP6C cells is therefore presumably a 
consequence of increased negative feedback phosphorylation due to ERK 
hyperactivation5,244, though we were unable to identify specific sites regulated by PPP6C 
(Figure 3.8C). In keeping with reports that BRAFV600E is insensitive to feedback 
phosphorylation5, its hyperphosphorylation did not affect its activity in vitro and is thus 
unlikely to impact MEK phosphorylation in cells. 
PPP6C regulates the level of RAF-mediated MEK activation loop phosphorylation 
without affecting the activity of RAF itself. MEK activation loop phosphorylation can be 
influenced by crosstalk regulation through phosphorylation at other sites, which could 
be subject to regulation by PPP6C. Indeed, we found that MEK1 phosphorylation at 
Ser298, which is mediated by PAK1 to promote activation loop phosphorylation244,245, 
was elevated in cells lacking PPP6C (Figure 3.8D). In contrast, there was no effect on 
phosphorylation at Thr286, a negative regulatory site phosphorylated by CDK1 or CDK5 
246,247. Because regulation by Ser298 phosphorylation is specific to MEK1 and not MEK2, 
we examined whether PPP6C selectively regulates MEK isoforms. We found that 
ectopically expressed MEK1 and MEK2 (upper bands), like endogenous MEK1/2 (lower 
bands), were both hyperphosphorylated when expressed in PPP6C-/- cells in comparison 
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to WT cells (Figure 3.8E). PPP6C therefore does not preferentially regulate one isoform 
of MEK but instead regulates both MEK1 and MEK2. This suggests that PPP6C regulates 
MEK activity by modulating activation loop phosphorylation independently of crosstalk 
pathway. 
 
3.2.3 MEK1/2 is a direct substrate of PP6 
As our findings above indicate PPP6C regulates MEK1/2 activation loop 
phosphorylation without affecting RAF activity, PPP6C likely promotes MEK1/2 
dephosphorylation, possibly acting directly. To assess PPP6C dephosphorylation of 
MEK, we isolated PP6 complexes by affinity purification from HEK293T cells ectopically 
expressing FLAG epitope-tagged PPP6C with PPP6R3 and ANKRD28. Complexes 
containing WT PPP6C dephosphorylated the activation loop residues (pSer218 and 
pSer222) of MEK1 in a manner sensitive to the pan-PP2A family phosphatase inhibitor 
okadaic acid (Figure 3.9A). Phosphatase inactive PPP6CD84N complexes had no activity 
against MEK1, indicating that our preparations were not contaminated with other MEK 
phosphatase activities. We found that PP6 also dephosphorylated pSer298 on MEK1, 
albeit with slower kinetics than with the activation loop sites, while it did not detectably 
dephosphorylate pThr286. Thus, PP6 dephosphorylates MEK1 selectively at the same 
sites that are elevated in cells lacking PPP6C (Figure 3.9C). Furthermore, PP6 had no 
activity on phospho-ERK2, consistent with PPP6C acting as a regulator of MEK (Figure 
3.9B). Overall, these studies demonstrate the direct dephosphorylation of MEK1 by PP6 
with substrate and phosphorylation site specificity (Figure 3.9C).  
To provide additional evidence that PPP6C acts directly on MEK, we performed 
co-immunoprecipitation experiments to determine if PP6 can interact with MEK in cells. 
HEK293T cells were transfected with plasmids expressing a FLAG epitope tagged PP6 
subunit (PPP6C, PPP6R1, PPP6R2, or PPP6R3) and untagged MEK1. We found that 
MEK1 co-immunoprecipitated with each of the PP6 regulatory subunits (Figure 3.9D), 
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with the amount of associated MEK1 proportional to the PPP6R expression level. 
Significantly less MEK1 associated with FLAG-tagged PPP6C. These results suggest 
that PP6 regulatory subunits serve to recruit MEK to the PP6 complex for 
dephosphorylation by PPP6C, consistent with a general role for non-catalytic subunits of 
PP6 and other PP2A family phosphatases in substrate binding149,153,155,248,249. In keeping 
with our observation that MEK binds to each of the regulatory subunits, we found that 
combined siRNA silencing of PPP6R1, PPP6R2 and PPP6R3, but not knockdown of 
individual subunits, significantly elevated MEK phosphorylation in 501mel cells (Fig 
3.9E). 
Our observations collectively suggest that PP6 has a general role as a MEK 
phosphatase across multiple cell types. Classical studies, however, had implicated 
PP2A as the major MEK phosphatase, suggesting that PP6 may act indirectly by 
regulating PP2A activity on MEK235,236. We therefore investigated the impact of PP6 and 
PP2A loss, alone and in combination, on MEK phosphorylation. We used siRNA 
SMARTpools to knockdown the two PP2A catalytic subunits (PPP2CA and PPP2CB) in 
PPP6C-/- and control 501mel cells (Figure 3.10A). In these cells, PPP2CA appeared to 
be the predominantly expressed isozyme, as PPP2CB siRNA alone did not detectably 
decrease total catalytic subunit levels. Knockdown of PPP2CA, but not PPP2CB, 
increased MEK activation loop phosphorylation levels in the control cell line. In PPP6C-/- 
cells, PP2A downregulation further increased MEK phosphorylation, with the two 
phosphatases having an apparently additive effect. Notably, loss of either phosphatase 
increased expression levels of the other, suggestive of a compensatory mechanism 
(Figure 3.10A, B). We further found that two other phosphorylation sites on MEK1, 
pThr292 and pSer298 were impacted by loss of PPP6C but not PP2A (Figure 3.10B). 
This experiment suggests that PP6 and PP2A act independently to dephosphorylate the 




Figure 3.7 PPP6C does not regulates ERK signaling via RAFs 
(A) shCTRL, shPPP6C-1, and shPPP6C-2 expressing 501mel cells were transfected with 
non-targeting control siRNA or siRNAs directed to ARAF, BRAF, or CRAF as indicated. 
Cells were lysed and assessed by immunoblot for phosphorylated and total MEK and 
ERK.  
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(B) Quantification of the relative levels of Phospho/Total MEK and ERK from (A) was 
normalized to shCTRL, siCONTROL. Data are represented as mean ± SD, n = 3. 
(C) 501mel cells expressing shCTRL, shPPP6C-1, or shPPP6C-2 were transfected with non-
targeting control siRNA or siRNA targeting both ARAF and CRAF. Cells were lysed and 
assessed by immunoblot for phosphorylated and total MEK and ERK. Knockdown of 




Figure 3.8 PPP6C regulates MEK and not BRAF 
(A) BRAF was immunoprecipitated from 501mel cells expressing shCTRL, shPPP6C-1, or 
shPPP6C and evaluated in vitro in kinase assays on MEK1 over the indicated time course. 
Vemurafenib (1 µM) was added to negative control reactions. Reactions were evaluated 
by immunoblot.  
(B) shCTRL, shPPP6C-1, and shPPP6C-2 501mel cells were treated with 1uM vemurafenib 
or 50nM trametinib for 24 hours as indicated. Cells were lysed and assessed by 
immunoblot for BRAF electrophoretic mobility shifts indicative of changes in 
phosphorylation.  
(C) PPP6C+/+ and PPP6C-/- 501mel cells were treated with 1uM vemurafenib or 50nM 
trametinib for 24 hours as indicated. Cells were lysed and assessed by immunoblot for 
phosphorylation at regulatory sites on BRAF. Quantification of the relative levels of 
Phospho/Total BRAF was normalized to PPP6C+/+. Data are represented as mean ± SD, 
n = 3. ***p<0.001, unpaired t-test. 
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(D) 501mel cells expressing shCTRL, shPPP6C-1, and shPPP6C-2 were lysed and assessed 
by immunoblot for MEK phosphorylation at Ser218/Ser222, Thr286, and Ser298. Non-specific 
cross-reacting bands in the pThr286 and pSer298 blots are indicated with an asterisk. 
Quantification of the relative levels of Phospho/Total MEK was normalized to shCTRL. Data 
are represented as mean ± SD, n = 3. 
(E) PPP6C+/+ and PPP6C-/- 501mel cell lines were transiently transfected to express His epitope 
tagged MEK1 or MEK2. Cell lysates were analyzed by immunoblot for phosphorylated and 
total MEK. Upper bands (open arrows) correspond to ectopically expressed His-tagged 





Figure 3.9 MEK1/2 is a direct substrate of PP6 
(A) PP6 complexes with WT or phosphatase inactive PPP6C (PD) were partially purified from 
HEK293T cells and incubated with phosphorylated MEK1 in vitro for the indicated times. 
Okadaic acid (OA, 100nM) was added where indicated. Reactions were evaluated by 
immunoblot. 
(B) In vitro phosphatase assays evaluating phospho-ERK2 as a PP6 substrate were carried 
out as in (A). Reactions were evaluated by immunoblot. 
(C) Quantification of in vitro phosphatase assays in (A) and (B). Remaining phosphorylation 
is shown relative to the 30 min control reaction. Data are represented as mean ± SD. For 
MEK1 pSer218/pSer222, n = 4; for all other data, n = 3. 
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(D) HEK293T cells were co-transfected to express the indicated FLAG epitope tagged PP6 
subunit and untagged MEK1. Anti-FLAG immunoprecipitates and whole cell lysates 
(WCL) were evaluated by immunoblot for MEK.  
(E) 501mel cells were transfected with non-targeting control siRNA or siRNA targeting 
PPP6R1, PPP6R2, and/or PPP6R3. Cells were lysed and assessed by immunoblot for 
phosphorylated and total MEK. Knockdown of PPP6Rs was also confirmed via 
immunoblot.  
(F) Quantification of the relative levels of Phospho/Total MEK in (E) was normalized to 




Figure 3.10 PP6 and PP2A regulate MEK independently 
(A) PPP6C+/+ and PPP6C-/- 501mel cells were transfected with non-targeting control siRNA or 
siRNA SMARTpools targeting PPP2CA and/or PPP2CB. Cells were lysed and evaluated 
by immunoblot for phosphorylated and total MEK. Quantification of the relative level of 
Phospho/Total MEK for PPP2CA/PPP2CB knockdown in PPP6C+/+ and PPP6C-/- cells. 
MEK phosphorylation was normalized to PPP6C+/+, siRNA Control. Data are represented 
as mean ± SD, n = 5. **p < 0.01, ***p < 0.001, unpaired t test. 
(B) PPP6C+/+ and PPP6C-/- 501mel cells were transfected with non-targeting control siRNA or 
siRNA SMARTpools targeting PPP2CA and PPP2CB. Cells were lysed and evaluated by 
immunoblot for phosphorylated and total MEK. Quantification of the relative levels of 
Phospho/Total MEK for PPP2CA/PPP2CB knockdown in PPP6C+/+ and PPP6C-/- cells. 
MEK phosphorylation was normalized to PPP6C+/+, siRNA Control. Data are represented 
as mean ± SD, n = 5. *p < 0.05, **p < 0.01, unpaired t test. 
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3.2.4 Cancer-associated PPP6C mutations abrogate PP6 phosphatase activity against 
MEK1/2 
PPP6C mutations are found across multiple cancer types but are most common 
in melanoma and other skin cancers, where they are thought to contribute to tumor 
development18,33,37,188,190. Prior characterization of PPP6C mutations has focused primarily 
on non-recurrent mutations that cluster at the catalytic center, which reportedly reduce 
or eliminate phosphatase activity. Interestingly, there are several PPP6C hotspot 
residues that are recurrently mutated, with R264C being the most common (Figure 1.4C). 
When modeled onto the X-ray crystal structure of a PPP5C-peptide complex250, sites of 
recurrent mutations are generally located within or proximal to the catalytic cleft (Figure 
3.11A). Of these, His55 appears critical for activity as it coordinates one of the bound 
metal ions (Figure 1.5A).  
We chose to characterize five of the most common mutations reported in 
melanomas (H55Y, P186S, P259S, R264C, and S270L) for their ability to regulate ERK 
signaling by ectopic expression in the PPP6C-/- 501mel cell line (Figure 3.10B). While re-
expression of WT PPP6C suppressed MEK and ERK phosphorylation to levels observed 
in parental cells, melanoma-associated PPP6C mutants varied in their impact on MEK 
and ERK phosphorylation (Figure 3.11B, C). In keeping with an essential role for His55 
in catalysis, cells expressing the H55Y mutant exhibited the highest level of MEK 
phosphorylation, similar to that seen in empty vector control cells. Cells expressing the 
P259S, R264C, and S270L mutants had moderate but significant increases in MEK 
phosphorylation compared to cells expressing WT PPP6C, suggesting partial loss of 
activity.  We note that the S270L mutant consistently expressed to lower levels than WT 
PPP6C or the other mutants, likely underlying its inability to promote MEK 
dephosphorylation. Ser270 maps to the globular core of the PPP6C catalytic domain 
(Figure 3.11A), potentially explaining the instability of the S270L mutation. Unlike the 
other mutants, expression of PPP6CP186S reduced MEK phosphorylation to a similar extent 
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as did the WT phosphatase. PPP6C mutants likewise impacted, to varying degrees, 
Aurora A phosphorylation in mitotically-arrested cells (Figure 3.11D, E). Expression of 
the H55Y, P259S, and S270L mutants resulted in high levels of Aurora A phosphorylation, 
similar to those seen in PPP6C-/- cells. Aurora A phosphorylation was more modest in 
cells expressing the PD, P186S, and R264C mutants, but still significantly higher 
phosphorylation than in cells expressing WT PPP6C.  We also examined the impact of 
PPP6C mutations on the levels of several transcriptional targets of ERK (DUSP6, ETV4 
and SPRY2, Figure 3.12). Elevated expression of all three targets were significantly 
suppressed upon re-expression of WT PPP6C in PPP6C-/- cells. The effect of PPP6C 
mutants generally correlated with their impact on MEK and ERK phosphorylation, with 
only levels of ETV4 being significantly affected by all mutants. 
We next performed clonogenic assays to examine the impact of PPP6C mutations 
on cell growth and MEKi sensitivity (Figure 3.13). We found that growth of the cells in the 
absence of drug inversely correlated with the degree of ERK pathway activation. For 
example, cells expressing the PPP6CH55Y mutant, which had the highest levels of MEK 
and ERK phosphorylation, grew equivalently to PPP6C-/- cells. Conversely, expression of 
PPP6CP186S, fully rescued the growth defect of null cells, in keeping with its complete 
reversal of MEK hyperactivation.  The other mutants, which partially impacted MEK and 
ERK phosphorylation, likewise grew at an intermediate rate. In all cases, treatment with 
low concentrations of MEKi at least partially reversed the growth impairment observed 
in cells expressing PPP6C mutants. Collectively, these experiments indicate that cancer-
associated PPP6C mutations generally cause partial loss-of-function, impacting both 
dephosphorylation of substrates and sensitivity. 
 
3.3 Discussion 
Our identification of PPP6C as a MEK phosphatase suggests that it also acts as a 
negative regulator of the core pathway driving melanoma, likely underlying at least in 
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part its role as a tumor suppressor. PPP6C mutations in melanoma almost exclusively 
co-occur with BRAF and NRAS mutations (Figure 1.4B), suggesting that alone they do 
not provide oncogenic levels of ERK signaling. In this context, downregulation of PPP6C 
is likely to have a role in tuning flux through the ERK pathway to counteract negative 
feedback regulation. A similar phenomenon may drive selection for mutations in MEK1, 
MEK2 and ERK2 found at low frequency in melanomas that generally co-occur with other 
activating lesions19,33,37,251. We note that like loss of PPP6C, these putatively oncogenic 
mutants suppress growth when delivered to cultured BRAF mutant melanoma cell lines, 
potentially reflecting different optimal levels of ERK signaling for cells in tumors in 
comparison with cells in culture.  
Most studies of PPP6C in melanoma have focused on its regulation of Aurora A, 
an essential kinase regulating mitotic spindle assembly and chromosome 
segregation152,190. Melanoma-associated PPP6C mutations impair its ability to 
dephosphorylate and inactivate Aurora A, resulting in genomic instability and DNA 
damage that may contribute to cancer progression189,190. Interestingly, Aurora A is 
reportedly a transcriptional target of oncogenic BRAF signaling in melanoma cells, 
suggesting that PP6 may coordinately regulate Aurora A through both direct 
dephosphorylation and through downregulation of ERK signaling252. This phenomenon 
may offer a therapeutic vulnerability, as melanoma cells expressing mutant PPP6C are 
sensitized to Aurora A inhibitors. 
The observation that loss or mutation of PPP6C is deleterious to cell growth may 
appear at odds with its role as a tumor suppressor and a negative regulator of ERK 
signaling. Recent studies indicate however that in the context of activating BRAF and 
RAS mutations, further elevation of signaling through the ERK pathway is toxic238,239,253,254. 
This phenomenon can give rise to inhibitor addiction, in which tumor cells treated with 
pathway inhibitors reactivate ERK signaling to re-establish signaling within an optimal 





Figure 3.11 Cancer-associated PPP6C mutations abrogate PP6 phosphatase activity against 
MEK1/2 
(A) PPP6C residues mutated in cancer are shown in spacefill representation modeled on the 
X-ray crystal structure of PPP5C in complex with a peptide substrate (PDB: 5HPE). The 
bound peptide is shown in cyan in stick representation, and the catalytic metal ions are 
shown as gray spheres.  
(B) PPP6C+/+ and PPP6C-/- 501mel cells were transduced to stably express GFP (-), WT 
PPP6C, or the indicated PPP6C mutants. Cells were lysed and assessed by immunoblot 
for phosphorylated and total MEK and ERK.  
(C) Phospho/Total MEK (black) and ERK (blue) signal ratios were quantified and normalized 
to the GFP-expressing PPP6C+/+ samples. Mean values ± SD are shown, n = 5. 
Significance is shown in comparison to PPP6C+/+ cells expressing GFP. *p < 0.05, **p < 
0.01, ***p<0.001, paired t test. 
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(D) Cells from (C) were treated with 100ng/mL nocodazole for 24 hours. Mitotic cells were 
lysed and assessed by immunoblot for phosphorylated and total Aurora A.  
(E) Phospho-Aurora A/Total Aurora A signal ratios were quantified (n = 5) and significance 




Figure 3.12 Cancer-associated PPP6C mutations upregulate ERK transcriptional targets  
PPP6C+/+ and PPP6C-/- 501mel cells were transduced to stably express GFP (-), WT 
PPP6C, or the indicated PPP6C mutants. Cells were lysed and assessed by immunoblot 
for ETV4, SPRY2, and DUSP6. Total protein signals were quantified and normalized to 
the GFP-expressing PPP6C+/+ samples. Mean values ± SD are shown, n = 3. Significance 
is shown in comparison to PPP6C+/+ cells expressing GFP. *p < 0.05, **p < 0.01, 




Figure 3.13 Cancer-associated PPP6C mutations decrease sensitivity to MEKi. 
PPP6C+/+ and PPP6C-/- 501mel cells were transduced to stably express GFP (-), WT 
PPP6C, or the indicated PPP6C mutants. Cells were cultured in media containing DMSO 
vehicle alone or the indicated trametinib concentration for 2 weeks in colony forming 
assays. Colonies were stained with crystal violet. Clonogenic growth was analyzed by 
ColonyArea in ImageJ and normalized to GFP-expressing PPP6C+/+ samples, n = 3. 
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leading to toxic hyperactive signaling outside of the fitness zone. In this context, even 
modest increases in ERK phosphorylation suppress growth, while further elevation 
induces cell death238. Toxicity and growth suppression due to ERK hyperactivation has 
been associated with a phenotypic switch mediated in part by downregulation of the 
melanocyte lineage-specific transcription factor MITF and by transcriptional 
upregulation of genes encoding secreted cytostatic proteins253,254. BRAFi and/or MEKi 
addicted melanoma tumors grown in mice regress when treatment with inhibitors is 
ceased238,253, suggesting periodic “drug holidays” could benefit patients who have 
progressed on BRAFi and MEKi. However, in clinical studies, cessation of BRAFi and/or 
MEKi therapy for several months re-sensitized to the inhibitors, though did not cause 
tumor regression255,256, revealing how the diversity of resistance mechanisms, tumor 
heterogeneity and adaptability complicate response to drug withdrawal in patients. Our 
studies suggest downregulation or inactivation of PPP6C as an unappreciated 
mechanism influencing inhibitor sensitivity. This substantiates the identification of PPP6C 
in modulating sensitivity to BRAFi in an insertional mutagenesis screen in a mouse model 
of melanoma, and to MEKi in CRISPR/Cas9 screens conducted in NRAS and KRAS 
mutant cells in culture140,143,257. 
The toxicity associated with high level ERK signaling indicates that tumor cells 
harboring hyperactivating BRAF or RAS mutations rely on negative feedback control to 
maintain signaling within the fitness zone. For example, silencing expression of the ERK 
phosphatase DUSP6 is toxic to BRAF mutant melanoma and KRAS mutant lung cancer 
cells258,259. Indeed, in genome wide CRISPR/Cas9 screens, dependency on DUSP6 was 
highly correlated with dependency on PPP6C across a panel of melanoma cells lines, in 
keeping with PPP6C as a key negative regulator of ERK signaling. We hypothesize that 
through dephosphorylation of MEK, PPP6C likewise contributes to negative feedback 
control of the ERK pathway. While we did not observe changes in levels of PPP6C upon 
inhibition of BRAF-MEK-ERK signaling, we cannot rule out transcriptional control of PP6 
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regulatory or scaffolding subunits as a mechanism of feedback regulation. Furthermore, 
because phosphorylation of PP6 regulatory subunits can mediate recruitment to 
substrates and other interaction partners249,260, targeting of MEK may be impacted by 
ERK-dependent phosphorylation or other modifications.  
Atypically for a tumor suppressor, more than half of melanoma-associated PPP6C 
mutations occur recurrently in hotspots (Figure 1.4C). While frameshift/truncation 
mutations are less common, they do appear to be associated with reduced progression-
free survival in melanoma186. Notably, non-recurrent mutations, while distributed in the 
primary sequence, do significantly cluster in the phosphatase catalytic center. Prior 
analysis of recurrent and non-recurrent PPP6C mutations indicate that all of them, to 
varying degrees, reduce catalytic activity189,190. These prior results are consistent with 
our observation that PPP6C mutations vary in their ability to suppress MEK 
phosphorylation. Given that PPP6C has been characterized as a “common essential” 
gene, it is possible that full loss of function is incompatible with cell proliferation. It has 
also been reported that PPP6C mutations weaken association with the PPP6R2 
regulatory and ANKRD28 scaffolding subunits190. While the three-dimensional structure 
of a PP6 heterotrimer has not yet been determined, in the X-ray crystal structures of the 
PP2A-B56 holoenzyme, the residue analogous to R264 participates in interactions 
between catalytic and regulatory subunit261. In contrast, the same residue is not at the 
catalytic-regulatory subunit interface in structures of other PP2A holoenzymes261,262. This 
raises the possibility that PPP6C mutations might change the heterotrimer composition, 
favoring some regulatory subunits over others, which could favor selective 
dephosphorylation of substrates in a manner that preserves cell viability. By analogy, 
recurrent cancer-associated mutations in the PP2A scaffolding subunit PPP2R1A 
preferentially disrupt interactions with some regulatory B subunits rather than causing 
complete loss of function191. The capacity for specific complexes to restrain cell 
proliferation is key to the activity of recently developed PP2A small molecule activators, 
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which stabilize specific holoenzymes263,264. As with PP2A, at least some PP6 substrates 
are recruited through interaction with individual regulatory subunits149,153,155,249, 
suggesting the potential for developing PP6 activators with therapeutic benefit.  
While our studies implicate PP6 as a MEK phosphatase, early reports suggested 
that MEK is dephosphorylated by PP2A235,236. Indeed, downregulation of PP2A activity 
by loss or mutation of its scaffolding subunit PPP2R1A causes resistance to MEK 
inhibitors in KRAS mutated lung and colorectal cancer cell lines191,265. Likewise, 
enhancing PP2A activity through downregulation of endogenous inhibitor proteins or 
through small molecule activators sensitizes to MEK inhibition265. However, in these 
contexts PP2A promotes sensitivity to MEKi by restraining bypass PI3K/mTOR signaling 
and by direct dephosphorylation of MYC or ERK itself. Likewise, the tumor suppressor 
function of PP2A is suggested to involve other processes, such controlling the stability 
of MYC and β-catenin266,267. Notably, in addition to restraining ERK signaling, PP2A can 
also promote MEK phosphorylation through dephosphorylation of inhibitory feedback 
phosphorylation sites on RAF and KSR234. Because oncogenic mutant BRAF signals 
independently of KSR and is feedback-resistant5, PP2A activity as a MEK phosphatase 
would not be counterbalanced by activation of upstream signaling. This phenomenon 
may explain our observation that like PP6, PP2A also contributes to MEK 
dephosphorylation in BRAF mutant 501mel cells. While we found that silencing PPP6C 
expression hyperactivates MEK in most cell lines we examined, this was not universally 
the case. The relative contributions of PP2A, PP6 and potentially other phosphatases to 
dephosphorylation of MEK is thus context dependent. Melanoma cells in particular are 
characterized by low PP2A activity, and the PP2A inhibitor protein CIP2A is an 
established transcriptional target of ERK signaling268,269. Interestingly, we observed that 
PP6 and PP2A catalytic subunit expression levels increase when the other is silenced 
(Figure 3.1A, B), suggesting compensation between the two complexes that could 
potentially influence dephosphorylation of any number of targets. Further work will be 
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necessary to understand the lineage-specific, signaling, or genetic contexts that dictate 
PPP6C regulation of MEK1/2.  
 87 
CHAPTER 4: FUNCTIONAL CONSEQUENCES OF RECURRENT SOMATIC CANCER-
ASSOCIATED MEK1 MUTATIONS AND DELETIONS 
 
4.1 Introduction 
MEK1 and MEK2 are dual specificity kinases that selectively activate ERK1/2 by 
phosphorylating a tyrosine and a threonine residue on its activation loop. Although MEK1 
and MEK2 are structurally similar, sharing 80% sequence identity, they have non-
redundant roles. MEK1 deficiency in mice is embryonic lethal whereas MEK2 deficiency 
in mice does not disrupt embryonic development270,271. It is thought that MEK1 can 
compensate for loss of MEK2 but not vice versa. MEK mutations observed in diseases 
are more commonly found in MEK1 (Figure 1.2), suggesting MEK1 has a more prominent 
role in development and disease. MEK1 has a core protein kinase catalytic domain with 
conserved features including a small N-lobe consisting of a 5-stranded β-sheet and αC-
helix and a large α-helix-rich C-lobe3,272 (Figure 4.1A). MEK1 has a proline rich insert 
unique to MEK1/2 in the protein kinase domain. The region N-terminal to the protein 
kinase domain contains a segment for ERK1/2 docking, a nuclear export sequence, and 
an inhibitory segment, also known as the negative regulatory region (NRR). The NRR, 
helix αA, stabilizes an inactive conformation of MEK1 by shifting the αC helix out of the 
active conformation. RAFs phosphorylate MEK1 at Ser218 and Ser222 of its activation 
loop, leading to conformational rearrangement into an active kinase conformation. Given 
the vital role of MEK1 in regulating fundamental cellular processes, MEK1 activity is 
highly regulated by intrapathway feedback mechanisms and cross-talk with other 
pathways (Figure 1.1A). Several regulatory and functional phosphorylation sites have 
been identified. MEK1 kinase activity is positively and negatively regulated by 
phosphorylation by PAK1, ERK1/2, and CDK53,245,273. Many of these phosphorylation 
events have MEK1 activity independent consequences including cross-talk with the 
PI3K-AKT pathway through regulation of PTEN localization4,274,275. MEK1 activity is also 
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regulated by scaffolding proteins276,277. For example, KSR associates with MEK and 
binds RAF and ERK upon growth factor stimulation278,279. 
It was originally assumed that because of the essential roles of MEK1 in 
fundamental cellular processes and for viability in mice, germline mutations in MEK1 
would be lethal. However, activating germline MEK1 mutations were first identified in 
cardio-facio-cutaneous (CFC) syndrome, a rare genetic disorder280. Somatic activating 
MEK1 mutations have been identified in various cancer types (Figure 4.1C). The first 
nonsynonymous MEK1 mutation associated with human cancer was discovered in an 
ovarian cancer cell line281. Since then, MEK1 mutations have been detected at low 
frequencies (4% or less) in lung adenocarcinoma282-284, chronic lymphocytic leukemia285, 
colorectal cancer286-289, and gastric cancer290,291. MEK1 mutations are reported to have a 
high prevalence in rare cancers such as hairy cell leukemia and Langerhans cell 
histiocytosis292-296. In melanoma, MEK1 mutations have been found to occur at an overall 
frequency of less than 8% in tumors18,19,287,297 (Figure 1.2), and identified in association 
with BRAF and MEK inhibitor resistant tumors87,101-103,298,299 suggesting MEK1 mutations 
as resistance mechanisms to targeted therapies. However, there is also evidence 
suggesting MEK1 mutations preexist in treatment-naïve tumors and do not correlate with 
inhibitor resistance300,301. MEK1 mutations in cancers overlap with those in CFC. The 
major mutational hotspot is the NRR (Figure 4.1B, C). Several recurrent mutations within 
the catalytic domain are in residues proximal to the N-terminal end of the NRR in the 
three-dimensional structure of MEK1. Of these mutations, P124S/L is the most frequent 
MEK1 mutation in melanoma. A recurrent in-frame deletion, ΔE102-I103, is located on 
the loop between N-lobe β3 strand and the αC helix (Figure 4.1A). Several other in-frame 
deletions at the b3-aC loop region presumably share similar mechanisms of activation 
with ΔE102-I103. Despite most mutations clustering to a similar spatial region, these 
mutations exhibit differing activities in overexpression studies and MEK inhibitor 
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sensitivity profiles297,302. It is therefore likely that distinct MEK1 mutations have differing 
mechanisms of activation. 
Elucidating the specific functional consequences of common somatic cancer-
associated MEK1 mutations is important for understanding how MEK1 mutations 
contribute to or drive tumorigenesis and drug resistance. We selected 8 recurrent MEK1 
mutations and in-frame deletions to investigate how MEK1 mutations alters activity 
(Figure 4.1B). Since we have completed these studies, other groups have published 
work with comprehensive biochemical and cellular characterization of tumor-associated 
MEK1 mutants, including our chosen mutants251,303. Our work presented here is 
consistent with the Rosen group’s findings.  
 
4.2 Results 
4.2.1 MEK1 mutations increase MEK1 kinase activity  
Cancer and CFC-associated MEK1 mutations have been widely characterized as 
gain-of-function mutations. To confirm our selected mutations as activating mutations 
and determine the level of kinase activity, MEK1 mutants, expressed and purified from 
HEK293T cells, were evaluated in in vitro kinase assays detecting MEK phosphorylation 
of ERK2.  ERK2 phosphorylation by each mutant was compared to ERK2 
phosphorylation by wild-type MEK1 (Figure 4.2). All MEK mutants we investigated have 
enhanced kinase activity against ERK2 compared to wild-type MEK1. The degree to 
which each mutation Is activating is highly variable. The activity of ΔE102-I103 deletion 
mutant is strikingly high (Figure 4.2B).  The signal intensity for phosphorylated ERK2 was 
well above the linear dynamic range of signal detection to accurately determine the fold 
increase in activity compared to that of wild-type MEK1 or any of the other mutants. The 
other deletion mutant, ΔQ58-E62, has an 8.9-fold increase in activity compared to wild-
type MEK1. The D67N mutant and the P124S mutant have modest increases in activity 
of < 3-fold. The remaining mutants are 4-7-fold more active than wild-type. The different  
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Figure 4.1 MEK1 Mutations 
(A) 3D crystal structure of MEK1. (PDB:3EQI). Selected mutations (red) and activation loop 
phosphorylation sites (yellow) are shown in stick representation. Bound ADP (white) is 
shown stick representation.  
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(B) Linear representation of MEK1 protein. Organization of nuclear export signal (NES), 
negative regulatory region (NRR), protein kinase domain, proline-rich insert, and ERK 
docking segment is color coded as indicated. Selected mutations and in-frame deletion 
are indicated in red. 
(C) Frequencies of MEK1 mutations reported in cancers 2 or more times. Data are from the 
cBioportal curated set of non-redundant studies.  
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levels of activation support the notion that mutations have different mechanisms of 
activation. The degree of ERK signaling activation in cells is likely influenced by the 
signaling context, in addition to structural consequences of the mutations. 
 
4.2.2 MEK1 mutations alter basal activation loop phosphorylation levels 
Upon phosphorylation at the activation loop, kinases undergo structural changes 
to adopt an active conformation. MEK1 is activated by RAF phosphorylation of its 
activation loop residues Ser218 and Ser222. MEK1 remains active until 
dephosphorylated at these sites by PP2A or, as we have shown in Chapter 3, PP6. 
Increased activation loop phosphorylation of MEK mutants may in part explain increased 
MEK activity. MEK1 mutants were examined for their relative levels of activation loop 
phosphorylation which we found were not necessarily correlative of their relative 
increases in activity (Figure 4.3). P124S and D67N mutants have reduced basal 
activation loop phosphorylation despite having higher activity than wild-type MEK1. The 
F53L mutant had the same basal phosphorylation levels as wild-type and 4-fold higher 
activity. The remaining mutants have higher activation loop phosphorylation than wild-
type MEK1. The activation loop phosphorylation of the ΔE102-I103 mutant is 
considerably higher than any other mutant and >40 fold higher than wild-type.  
 The inconsistency between basal activation loop phosphorylation and kinase 
activity identifies distinct groups of mutations. P124S and D67N mutants are 
underphosphorylated, suggesting their modest increases in basal activity is not 
attributed to increased activation by upstream RAFs. The F53L, K57N, C121S, E203K, 
and ΔQ58-E62 mutants have more correlative activation loop phosphorylation levels and 
activity levels. In these cases, activation loop phosphorylation most likely contributes to 
increased kinase activity. The extremely high levels of activation loop phosphorylation 
and activity of ΔE102-I103 suggest factors other than activating phosphorylation are 
involved in its mechanism of action. 
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4.2.3 MEK1 mutations can disrupt or enhance binding to regulatory binding partners 
MEK activity is regulated by key binding partners. BRAF-MEK1 complexes are 
enriched in wild-type BRAF cells and mutant RAS cells304. Pathway activation induces 
BRAF dimerization and phosphorylation of MEK1 which then dissociates from BRAF to 
activate ERK. Depending on the genetic background, MEK1 mutations may alter MEK1 
interactions with RAFs impacting pathway activation. Additionally, KSR1 scaffolding 
protein binds MEK1 via the proline-rich region to regulate MEK activation by RAF279. In 
the context of wild-type BRAF (HEK293T cells), most MEK1 mutants immunoprecipitated 
similar amounts of CRAF, BRAF, and KSR1 (Figure 4.4). Interestingly, the C121S 
mutation disrupts interaction with CRAF, BRAF, and KSR1. The ΔQ58-E62 and ΔE102-
I103 deletion mutants do not bind BRAF as well as wild-type MEK1 but bind similarly to 
CRAF and KSR1. This is not surprising given these deletion mutants have the highest 
activation loop phosphorylation levels, which favors dissociation from BRAF.  
Interestingly, P124S has enhanced interactions with BRAF and CRAF, which is 
consistent with P124S having the lowest activation loop phosphorylation levels.  
 MEK1 mutant interactions with other binding partners should be explored for their 
consequences on MEK1 signaling. Changes in binding to MEK phosphatases and 
substrates (ERK1/2) directly impact signaling propagation further downstream. 
 
4.3 Discussion 
 Our work characterizing MEK1 mutations, though limited, provide key 
insight into MEK1 mutant activation and the genetic contexts they are observed in. The 
wide range of activation levels observed with MEK1 mutations is surprising because ERK 
pathway activation promotes cell fitness only when within an optimal range. Low and 
high pathway activation can be toxic to cells. The extreme ERK activation with the ΔE102-
I103 mutation is unlikely to be tolerable in contexts where ERK activation is already 
elevated. In patient samples, this deletion does not co-occur with mutations in other ERK  
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Figure 4.2 MEK1 mutations increase MEK1 kinase activity 
(A) MEK1 wild-type (WT), kinase dead (KD), and mutants were purified from HEK293T cells 
and incubated with ERK2 for 30 minutes. Reactions were evaluated by immunoblot. 
Quantification of ERK2 phosphorylation levels shown relative to the WT reaction. n = 2. 
(B) MEK1 wild-type (WT) and ΔE102-I103 deletion mutant (EIdel) kinase reactions run 
parallel to reactions in (A). Reactions were evaluated separately to avoid signal 
interference from hyperphosphorylated ERK. 
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Figure 4.3 MEK1 mutations alter basal activation loop phosphorylation levels 
MEK1 wild-type (WT), kinase dead (KD), and mutants were purified from HEK293T cells 
evaluated by immunoblot for MEK phosphorylation at S218 and S222. Quantification of 
MEK1 phosphorylation levels shown relative to the WT reaction. n = 3. 
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Figure 4.4 MEK1 mutations can disrupt or enhance binding to regulatory binding partners 
MEK1 wild-type (WT), kinase dead (KD), and mutants were purified from HEK293T cells 




pathway components and are present only in the triple wild-type genetic subtype of 
melanoma77,305. However, mutations with modest increases in activity, like P124S and 
D67N, commonly occur with BRAF mutations, NRAS mutations, NF1 mutations, or other 
MEK1 mutations. Interestingly, MEK1 mutations are generally not present in cancer types 
with low RAS and RAF mutation rates.  
In the context of BRAFi resistance, C121S, E203K, and K57N mutations have 
been detected in progressive tumors but not in patient-matched MAPKi naïve 
tumors101,102,299. The moderate increases in ERK activity for these mutations contribute to 
acquired resistance to BRAFi through MAPK reactivation. However, P124 mutations 
found in progressive tumors were also present in treatment naïve tumors of the same 
patient89,300,301. Pre-existing P124 mutations are associated with poorer response and 
shorter progression free survival with BRAFi therapy compared to wild-type MEK1. 
Progressive tumors from patients with pre-existing P124 mutations acquire NRAS 
mutations or BRAF amplification for BRAFi resistance91,300. The modest elevation in MEK1 
activity from P124 mutations may contribute to drug resistance but is insufficient to 
confer resistance alone.  
Many MEK1 mutations and deletions map to or spatially near the NRR. Loss or 
interruption of the helical secondary structure of the NRR results disrupts its stabilization 
of an inactive conformation and results in elevated MEK1 activation independent of 
activation loop phosphorylation306. ΔQ58-E62, F53L, K57N, and D67N are a part of the 
NRR helix, (Figure 4.1A). P124S, E203K, and C121D map to regions spatially proximal 
and potentially interacting with the NRR helix. The disparate activity levels and activation 
loop phosphorylation levels of these mutants we observed show the activating 
mechanisms of these mutations are more complex than just the relief of an intramolecular 
negative regulatory mechanism. ΔE102-I103 is a deletion in the b3-aC loop. Similar 
activating deletions in the b3-aC loop have been detected in EGFR and BRAF231,307. 
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These deletions presumably constrain the aC helix in an active conformation.  
Our findings were consistent with the Rosen group’s characterizations of these 
mutants251. They identify 3 classes of MEK1 mutations. Class 1 mutants are dependent 
on the activation loop phosphorylation by RAF for hyperactivation and always co-occur 
with RAS, RAF, and NF1 mutations in tumors. This class include the D67N and P124S 
mutants we characterized to have modest increases activation with decreased activation 
loop phosphorylation compared to wild-type MEK1. The authors demonstrate that 
additional phosphorylation of these mutants beyond the basal levels result in 
hyperactivated MEK1. Class 2 mutants have elevated intrinsic activity that is further 
activated by RAF phosphorylation of the activation loop. These mutations can sometimes 
co-occur with RAS, RAF, or NF1 mutations in tumors and are associated with acquired 
BRAFi resistance. The F53L, K57N, C121S, and E203K are class 2 mutations. We found 
these mutations to have moderate increases activity and activation loop phosphorylation 
compared to wild-type MEK. Class 3 mutants, which are b3-aC loop region deletions, 
autophosphorylate and therefore are activation loop phosphorylation independent and 
intrinsically hyperactive. There is evidence that these deletion mutations promote MEK1 
homodimerization and intradimer cross-phosphorylation of activation loops303. These 
mutations, which include the hyperactive and hyperphosphorylated ΔE102-I103 deletion 
mutant from our studies, do not co-occur with RAS, RAF, or NF1 mutations. 
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CHAPTER 5: CONCLUDING REMARKS 
 
 The ERK signaling pathway is one of the most thoroughly investigated signaling 
pathways. With increasing activation, ERK signaling proceeds from stimulating cell 
growth and proliferation to promoting malignant transformation and then to inducing 
cytotoxicity at extremely high levels of pathway activation. Accordingly, the ERK 
signaling cascade is central to a broader and more complex signal transduction 
network. This includes a multitude of regulators and regulatory mechanisms which have 
been exhaustively studied and described. Mutations or other alterations in the cascade 
or this extended network shifts signaling levels to initiate tumorigenesis or MAPKi 
resistance. In this dissertation, 
we describe the identification of modulators of MEKi sensitivity in melanoma, discovery 
of a novel MEK regulator, and the biochemical and cellular characterization of cancer-
associated genetic lesions.  
Establishing PP6 as a MEK phosphatase provides a mechanistic explanation 
supporting previous assumptions of PPP6C being a tumor suppressor based on 
occurrences of PPP6C mutations in melanoma. In terms of potential clinical implications, 
our work characterizing melanoma-associated PPP6C mutations suggests these loss-of-
function mutations may be predictive of poor or limited response to MAPKi therapy. 
Conversely, activating PPP6C may sensitize cells to MAPKi. The recent development of 
small molecule PP2A activators that stabilize specific PP2A holoenzymes263,264 
demonstrate the potential for development of PP6 activators for use in combination with 
other MAPKi to treat BRAFV600E melanoma.  
Our characterization of both cancer-associated MEK1 mutations and PPP6C 
mutations demonstrates how activating mutations in an oncogene and loss-of-function 
mutations in a tumor suppressor can result in similar signaling consequences These 
mutations all result in MEK activation which has clear implications for these mutations in 
tumorigenesis and MAPKi response. However, the levels of MEK activation are highly 
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variable among all MEK and PPP6C mutants indicating a diversity in the mechanisms of 
activation and physiological consequences. 
Expanding the intricate ERK signaling regulatory network to include PP6 raises 
new questions related to PP6 involvement in the numerous ERK signaling cellular 
functions in normal and pathological conditions. These questions, many of which are 
posed in chapter discussion sections (2.3, 3.3) include determining the specific contexts 
that govern PP6 regulation of MEK and understanding the functions and distribution of 
different PP6 holoenzymes. However, in addition to revealing what is not yet understood 
about PPP6C, the work presented in this dissertation principally contributes to our 








REAGENT or RESOURCE SOURCE IDENTIFIER 
Antibodies 
PPP6C, rabbit polyclonal Bethyl Laboratories, Inc 
Cat# A300-844A; 
RRID: AB_2168899 
Phospho-MEK1/2 (Ser217/221), rabbit polyclonal Cell Signaling Technology 
Cat# 9121; RRID: 
AB_331648 




Cat# 3958; RRID: 
AB_2138014 
Phospho-MEK1 (Ser298), rabbit polyclonal Cell Signaling Technology 
Cat# 9128; 
RRID:AB_330810 
Phospho-MEK1 (Thr286), rabbit polyclonal Cell Signaling Technology 
Cat# 9127; RRID: 
AB_331654 
MEK1/2, rabbit polyclonal Cell Signaling Technology 
Cat# 9122; RRID: 
AB_823567 
MEK1/2 (L38C12), mouse monoclonal Cell Signaling Technology 
Cat# 4694; RRID: 
AB_10695868 
P44/42 MAPK (ERK1/2), rabbit polyclonal Cell Signaling Technology 
Cat# 9102; RRID: 
AB_330744 
Phospho-p44/42 MAPK (ERK1/2) (Thr202/Tyr204) 
(E10), mouse monoclonal 
Cell Signaling 
Technology 
Cat# 9106; RRID: 
AB_331768 




RAF-1 (C-12), rabbit polyclonal Santa Cruz Biotechnology 
Cat# sc-133; RRID: 
AB_632305 
A-RAF (D2P9P), rabbit monoclonal Cell Signaling Technology 
Cat# 75804; RRID: 
AB_2799875 




Cat# 3079; RRID: 
AB_2061481 
Aurora A (1F8), mouse monoclonal Cell Signaling Technology 
Cat# 12100; RRID: 
AB_2797820 
PP2A C Subunit (52F8), rabbit monoclonal Cell Signaling Technology 
Cat# 2259; RRID: 
AB_561239 
Caspase-3, rabbit polyclonal Cell Signaling Technology 
Cat# 9662; RRID: 
AB_331439 
PARP (46D11), rabbit monoclonal Cell Signaling Technology 
Cat# 9532; RRID: 
AB_659884 
ETV4, rabbit polyclonal Proteintech Cat# 10684-1-AP; RRID: AB_2100984 
DUSP6/MKP3, rabbit polyclonal Cell Signaling Technology 
Cat# 39441; RRID: 
AB_2799156 
SPRY2 (D3G1A), rabbit monoclonal Cell Signaling Technology 
Cat# 14954l RRID: 
AB_2798658 
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Phospho-BRAF (Ser445), rabbit polyclonal Cell Signaling Technology 
Cat# 2696; RRID: 
AB_390721 




Phospho-BRAF (Thr753), rabbit polyclonal Invitrogen Cat# PA5-37498; RRID: AB_2554107 




Cat# 26975; RRID: 
AB_2798935 
KSR1, rabbit polyclonal Cell Signaling Technology 
Cat# 4640; RRID: 
AB_ 10544539 
Normal mouse IgG Santa Cruz Biotechnology 
Cat# sc-2025; 
RRID: AB_737182 
FLAG M2, mouse monoclonal Sigma Cat# F3165; RRID: AB_259529 
Penta-HIS, mouse monoclonal Qiagen Cat# 34660; RRID: AB_2619735 








Chemicals, Peptides, and Recombinant Proteins 
Selumetinib (AZD6244) SelleckChem Cat# S1008 
Trametinib (GSK1120212) SelleckChem Cat# S2673 
Vemurafenib (PLX4032) SelleckChem Cat# S1267 
Puromycin Thermo Fisher Scientific Cat# A1113803 
Nocodazole Sigma Cat# M1404 
Okadaic Acid Enzo Life Sciences Cat# ALX-350-063 
3xFLAG peptide Sigma Cat# F4799 
Anti-FLAG M2 affinity gel Sigma Cat# A2220 
Critical Commercial Assays 
QuikChange II Kit Agilent Cat# 200521 
Gateway LR Clonase II Enzyme Kit Thermo Fisher Scientific Cat# 11791100 
Lipofectamine RNAiMAX Reagent Thermo Fisher Scientific Cat# 13778100 
DNeasy Blood and Tissue Kit Qiagen Cat# 69504 
Pierce BCA Protein Assay Thermo Fisher Scientific Cat# 23250 
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Experimental Models: Cell Lines 
501mel (human) 




A375 (human) Laboratory of Harriet Kluger  
YUGEN8 (human) 
























SK-MEL-103 (human) Laboratory of Narendra Wajapeyee  
SK-MEL-30 (human) Laboratory of Craig Crews  
M318 (human) Laboratory of Narendra Wajapeyee  
MEL-ST (human) Laboratory of Narendra Wajapeyee  
A549 (human) ATCC Cat# CCL-185; RRID: CVCL_0023 
HCT116 (human) ATCC Cat# CCL-247; RRID: CVCL_0291 
SW620 (human) ATCC Cat# CCL-227; RRID: CVCL_0547 
RKO (human) ATCC Cat# CRL-2577; RRID: CVCL_0504 
U2OS (human) ATCC Cat# HTB-96; RRID: CVCL_0042 
HEK293T (human) ATCC Cat# CRL-11268; RRID: CVCL_1926 
Bacterial Strains 
MAX efficiency DH5a Thermo Fischer Scientific Cat# 18258012 
One Shot Stbl3 Thermo Fischer Scientific Cat# C737303 
Oligonucleotides 
CRISPR PPP6C sgRNA 2a 
(CACCGTGAGAGTAGACAGATAACAC)   
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CRISPR PPP6C sgRNA 2b 
(AAACGTGTTATCTGTCTACTCTCAC)   
CRISPR PPP6C Sequencing Primer F 
(CAGATTCTTGTAGATTTCCCTGGAATC)   
CRISPR PPP6C Sequencing Primer R 
(CTTTGAGGCACAGATCTAGAAAGATG)   
BRAF siRNA 
(UCUGUAAGGCUUUCACGUUAUA) Horizon Discovery  
ARAF siRNA 
(UUUCGUCCCUUGAUGAGUCGGU) Horizon Discovery  
CRAF siRNA 
(UCUCUGAAAACAUGUGUUCUGC) Horizon Discovery  
siGENOME Non-Targeting siRNA #2 Horizon Discovery Cat# D-001210-02-05 
ON-TARGETplus Human PPP2CA (5515) siRNA – 
SMARTpool Horizon Discovery 
Cat# L-003598-01-
0005 
ON-TARGETplus Human PPP2CB (5516) siRNA – 
SMARTpool Horizon Discovery 
Cat# L-003599-00-
0005 
ON-TARGETplus Human PPP6R1 siRNA (A) Horizon Discovery Cat# J-020420-09-0002 
ON-TARGETplus Human PPP6R1 siRNA (B) Horizon Discovery Cat# J-020420-10-0002 
ON-TARGETplus Human PPP6R2 siRNA (A) Horizon Discovery Cat# J-021331-09-0002 
ON-TARGETplus Human PPP6R2 siRNA (B) Horizon Discovery Cat# J-021331-11-0002 
ON-TARGETplus Human PPP6R3 siRNA (A) Horizon Discovery Cat# J-014646-09-0002 
ON-TARGETplus Human PPP6R3 siRNA (B) Horizon Discovery Cat# J-014646-10-0002 
Recombinant DNA 
pSpCas9(BB)-2A-GFP (PX458) Addgene Cat# 48138 
pSpCas9(BB)-2A-GFP_hPPP6C-2   
pDONR223_PPP6C_WT Addgene Cat# 81811 
pLEX_305 Addgene Cat# 41390 
pLEX_305-PPP6C-WT   
pLEX_305-PPP6C-D84N   
pLEX_305-PPP6C-H55Y   
pLEX_305-PPP6C-P186S   
pLEX_305-PPP6C-P259S   
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pLEX_305-PPP6C-R264C   
pLEX_305-PPP6C-S270L   
pLEX_305-GFP   
pLKO.1_shPPP6C-1 Sigma TRCN0000379835 
pLKO.1_shPPP6C-2 Sigma TRCN0000002767 
pREP4-MEK1 [308]  
pcDNA3-His6-MEK1 [309]  
pcDNA3-His6-MEK1-K57N   
pcDNA3-His6-MEK1-F53L   
pcDNA3-His6-MEK1-D67N   
pcDNA3-His6-MEK1-C121S   
pcDNA3-His6-MEK1-P124S   
pcDNA3-His6-MEK1-E203K   
pcDNA3-His6-MEK1-ΔQ58-E62   
pcDNA3-His6-MEK1- ΔE102-I103   
pcDNA3-His6-MEK1-K97M   
pcDNA3-His6-MEK2   
pGEX4T3_ERK2 [310]  
pET22b-MEK1 Laboratory of Titus Boggon  
pET22b-MEK1-DE102_I103   
pFLAG-BRAF-V600E   
pFLAG-PPP6C   
psPAX2 Addgene Cat# 12260 
pCMV-VsV-G Addgene Cat# 8454 
pCMV-dR8.91   
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pV1900 [311]  
pV1900-PPP6R3   
pV1900-ANKRD28   
pFLAG-PPP6R1   
pFLAG-PPP6R2   
pFLAG-PPP6R3   
Software and Algorithms 
GENE-E Broad Institute https://software.broadinstitute.org/GENE-E/ 
GraphPad Prism GraphPad https://www.graphpad.com 





PYMOL Schrodinger https://pymol.org/ 
Image Studio Lite LI-COR Biosciences https://www.licor.com/bio/image-studio-lite/ 
ImageJ NIH https://imagej.nih.gov/ij/ 







Cell Lines and Culture Conditions 
501mel, YUGEN8, YUZEAL, YUSIK, YURIF, and YUGASP cells were cultured in Opti-
MEM medium (Gibco) supplemented with 5% fetal bovine serum (FBS) (Gibco) and 1% 
penicillin/streptomycin (P/S, Gibco). A375 cells were cultured in Opti-MEM medium 
supplemented with 10% FBS and 1% P/S. MEL-ST, U2OS, and HEK293T cells were 
cultured in DMEM medium (Gibco) supplemented with 10% FBS and 1% P/S. SK-MEL-
103, SK-MEL-30, HCT116, and M318 cells were cultured in RPMI 1640 medium (Gibco) 
supplemented with 10% FBS and 1% P/S. RKO were cultured in MEM medium (Gibco) 





Plasmids, Cloning, and Mutagenesis 
Plasmids harboring cDNAs of PPP6C, PPP6R1, PPP6R3 and ANKRD28 in pDONR223 
were from the human ORFeome collection (v8.1), and the PPP6R2 cDNA was from 
Transomic. The lentiviral expression vector pLEX_305-PPP6C and the transient 
expression plasmid pVL1900-ANKRD28 (untagged) were generated by Gateway 
recombination cloning into their respective destination vectors. The untagged 
expression vector for PPP6R3 used for preparation of PP6 complexes was generated by 
Gateway recombination into pV1900 followed by QuikChange mutagenesis to insert a 
stop codon upstream of the FLAG tag. The transient expression vector for N-terminally 
FLAG-tagged PPP6C, PPP6R1, PPP6R2 and PPP6R3 were made by PCR amplification 
of the coding sequence from the source plasmid and inserting into pcDNA3-FLAG by 
either Gibson assembly (PPP6R3) or restriction enzyme cloning (all others). The 
mammalian expression vector for N-terminally 6xHis-tagged MEK2 was generated by 
shuttling the entire coding sequence from pRSET-MEK2 (obtained from the laboratory of 
Natalie Ahn) and into pcDNA3. All mutants were generated using QuikChange Site 
Directed Mutagenesis following standard protocols. Constructs were verified by Sanger 
sequencing through the entire open reading frame. 
 
Recombinant Lentivirus Production and Cell Infection 
shRNA lentiviruses were packaged in low passage HEK293T cells by polyethylenimine 
(PEI) co-transfection with packaging constructs dR8.91 and VsV-G (Addgene, 8454). 
PPP6C expression lentiviruses were packaged in low passage 293T cells by PEI co-
transfection with packaging constructs psPAX2. (Addgene, 12260) and VsV-G 
(Addgene, 8454). For PEI co-transfection, lentiviral transfer plasmid:packaging 
plasmid:envelope plasmid ratio was at 10:10:1 with the PEI:DNA ratio at 3:1. Supernatant 
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media containing virus was collected at 48 hours post transfection. Cells were infected 
with lentivirus at an MOI of 0.3-0.4 in the presence of 4ug/mL polybrene for 24 hours and 
selected for >48 hours in fresh media containing (1.5-2.5 ug/mL) puromycin.  
 
shRNA Screening 
The shRNA library was custom generated by pooling human MISSION shRNA constructs 
(Sigma) targeting all annotated protein kinases and phosphatases and packaged into 
lentiviral particles as described above. To initiate the screen, 501mel cells were 
transduced for 24 hours with the lentiviral library in 0.4 µg/ml polybrene at an MOI of 0.3 
to assure that most cells receive a single viral integration. A sufficient number (8 x 106) 
of cells were infected to ensure >1,000-fold coverage for each unique shRNA in the 
library for a reference sequencing sample and for each drug condition. Infected cells 
were selected with 1.8 µg/mL puromycin for 48 hours, trypsinized, and 8 x 106 cells were 
reserved for the T0 reference sample. For the remainder, 8 x 106 cells were plated for 
each of the 5 conditions: 0.0001% DMSO vehicle control, 1 nM trametinib, 3.3 nM 
trametinib, 33 nM selumetinib, and 100 nM selumetinib. Every two doublings, cells were 
counted, and 8 x 106 cells were replated for propagation. The screen was carried out for 
10 total population doublings (T10). Genomic DNA from the T0 and T10 samples for each 
of the drug conditions was extracted using Qiagen DNeasy Blood and Tissue Kit 
(Qiagen, Cat No. 69504), following the manufacturer’s protocol. For each drug 
condition/time point sample, the shRNA integrants were PCR-amplified from the genomic 
DNA with barcoded primers and sequenced on an Illumina HiSeq instrument. The RIGER 
algorithm in GENE-E (www.broadinstitute.org/cancer/software/GENE-E/) was used to 
rank each gene by their enrichment.  
 
MEKi Dose Response Assays  
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Cells (750 per well) were seeded in 96-well black/clear bottom plates, allowed to recover 
overnight, and treated with varying concentrations of trametinib or selumetinib (6 
wells/concentration) in fresh media for 72 h.  Media aspirated and replaced with fresh 
media containing 44 µM resazurin (alamarBlue Cell Viability Reagent, Fisher Scientific). 
Plates were incubated in the dark for 4 hours at 37°C, and fluorescence (excitation 560 
nm; emission 590nm) was measured on a plate reader.  When MEKi treatment was 
initiated, starting time reading was obtained on a separate plate containing untreated 
cells. Starting point readings were subtracted from the 72 h readings to measure overall 
growth inhibition. Dose response curves were generated with GraphPad Prism.  
 
Clonogenic Growth Assays 
Cells (1 x 103) were plated in each well of a six-well plate containing 3 mL of media with 
or without MEKi and cultured at 37°C under 5% CO2 undisturbed for 14 days. Media was 
removed, and cells were gently washed with PBS. The cells were stained with crystal 
violet staining solution (0.5% crystal violet, 6% formaldehyde, 1% methanol in PBS) for 
15 min and washed 3 times with water. Plates were air-dried and imaged. For 
experiments characterizing PPP6C mutants, cells (2.5 x 103) were plated in 12 well plates 
containing 1 mL media with or without MEKi. 
Cell Lysis and Immunoblot Analysis 
Cells were placed on ice, washed twice with cold PBS, and lysed in cold lysis buffer (20 
mM Tris [pH 8.0], 137 mM NaCl, 10% glycerol, 1% Igepal CA-630, 1 mM PMSF, 1 mM 
Na3VO4, 10 µg/mL leupeptin, 2 µg/mL pepstatin A, 10 µg/mL aprotinin) for 15 min. Cell 
lysates were scraped into 1.5 mL tubes and clarified in a 4 °C microcentrifuge at 13,000 
rpm for 10 min. Cleared lysates were analyzed by BCA protein assay. 4X SDS-PAGE 
loading buffer was added to lysates to prepare immunoblot samples. Equal amounts of 
lysate (15 µg per lane) were fractionated by SDS-PAGE and transferred to polyvinyl 
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difluoride (PVDF) (Sigma, IPFL85R) membrane. Membranes were blocked in Tris 
buffered saline (TBS) with 5% non-fat milk for one h and probed overnight at 4 °C with 
primary antibodies diluted according to manufacturer’s recommendations. Membranes 
were incubated for 1 h in fluorescently-labeled secondary antibodies diluted 1:10,000 in 
TBS with 5% bovine serum albumin (BSA) and 0.1% Tween20. Western blots were 
imaged with an Odyssey CLx imaging system (LI-COR Biosciences), and densitometry-
based quantification was carried out with Image Studio Lite. 
 
Co-immunoprecipitation 
HEK293T cells in 10 cm plates were transiently transfected with equal amounts of pREP-
MEK1 (untagged) and FLAG tagged PP6 subunit plasmid precomplexed with 
polyethyleneimine (PEI) at a 3:1 ratio with DNA. After 48 h, cells were placed on ice and 
washed twice with cold PBS. On the second PBS wash, cells were scraped into 1.5 mL 
tubes and pelleted at 1000 rpm for 5 min.  Cells were resuspended in 300 µL hypotonic 
lysis buffer (10 mM Tris-HCl [pH 8.0], 1 mM KCl, 1.5 mM MgCl2, 0.5 mM DTT, 0.05% 
Igepal CA-630, 1 mM PMSF, 1 mM Na3VO4, 10 µg/mL leupeptin, 2 µg/mL pepstatin A, 
10 µg/mL aprotinin) and kept on ice for 5 min. Cell lysates were vortexed for 1 minute 
and run three times through a 25G needle with a syringe. Lysates were spun at 3500 
rpm for 10 minutes in a 4°C microcentrifuge. A portion (30 µL) of the supernatant was 
reserved for analysis of the whole cell lysate sample. The remaining total supernatant 
was brought to a volume of 500 µL with additional hypotonic lysis buffer, and the [NaCl] 
was adjusted to 150 mM. Anti-FLAG M2 Affinity Gel beads (Sigma, A2220) were blocked 
in 5% BSA-TBS solution for 1 h, equilibrated to hypotonic lysis buffer, and 30 µL of the 
suspension was added to each supernatant. Samples were rotated at 4°C overnight. 
Beads were pelleted and washed with cold wash buffer 1 (20 mM Tris [pH 7.5], 150 mM 
NaCl, 1% Triton X-100, 2.5 mM Na4P2O7, 1 mM b-glycerophosphate, 3 mM b-
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mercaptoethanol, 1 mM PMSF, 1 mM Na3VO4, 10 µg/mL leupeptin, 2 µg/mL pepstatin A, 
10 µg/mL aprotinin) for 10 minutes, followed by one quick and one 10 min wash with 
cold wash buffer 2 (50 mM HEPES [pH 7.4], 150 mM NaCl, 3 mM b-mercaptoethanol, 
0.1 mM Na3VO4, 0.01% Igepal CA-630, 10% glycerol). Beads were resuspended in 30 
µL 2X SDS buffer (100mM Tris-Cl [pH 6.8], 4% SDS, 20% glycerol) and boiled for 5 min. 
Samples were centrifuged in Whatman UNIFILTER 0.45 µm plates (Sigma, 
WHA77002808) at 4000 rpm for 10 minutes to remove beads, and 4X SDS-PAGE loading 
buffer was added to filtrates. Samples were analyzed via immunoblot as described 
above. 
 
Generation of CRISPR/Cas9 Knockout Cell Lines  
CRISPR/Cas9 constructs were generated by cloning sgRNA sequences into 
pSpCas9(BB)-2A-GFP (Addgene, 48138) according to the cloning protocol established 
by the Zhang lab (https://www.addgene.org/browse/article/7475/). Two sets of sgRNA 
oligos were used but only one sgRNA targeting exon 4 resulted in PPP6C knockout 
clones. pSpCas9(BB)-2A-GFP was used to generate negative control clones. 501mel 
cells were transfected with CRISPR/Cas9 constructs via PEI, and 48 hours post 
transfection, cells were trypsinized. After centrifugation and removal of media/trypsin, 
cells were resuspended in PBS and transferred to FACS tubes. Single GFP positive cells 
were sorted into 96 well plates via a BD FACSAria instrument. 96 well plates were treated 
with 0, 1, or 2 nM trametinib and incubated for several weeks until colonies were 
observed. PPP6C knockout 501mel cell colonies only grew out in the presence of 
trametinib and were maintained in 1-2 nM trametinib but withdrawn from trametinib >24 
h before experiments. PPP6C knockout was confirmed by immunoblot and sanger 




MEK1 and MEK1 mutants were expressed in HEK293T cells by PEI transfection with 
pcDNA3-His-MEK1 alone or in a 4:1 ratio with pFLAG-BRAF-V600E to generate 
phosphorylated MEK1 (for PP6 phosphatase assays). After 40 h, plates were put on ice 
and washed once with ice-cold PBS. To lyse cells, 1 mL ice cold lysis buffer (20 mM Tris 
[pH 7.5], 150 mM NaCl, 1% Triton X-100, 2.5 mM Na4P2O7, 1 mM b-glycerophosphate, 
1mM Na3VO4, 3 mM b-mercaptoethanol, 1 mM PMSF, 10 µg/mL leupeptin, 2 µg/mL 
pepstatin A, 10 µg/mL aprotinin) was added to each plate. Lysates were scraped into 
1.5 mL tubes, incubated on ice for 10 minutes, and clarified in a microcentrifuge at 
13,000 rpm for 10 min at 4°C. Supernatants were transferred to fresh tubes, and 50 µL 
of Talon resin (Takara) was added. Samples were rotated for 2 hours at 4 °C. Beads 
were pelleted for (2 min, 4000 rpm) at 4°C microcentrifuge, washed twice with lysis buffer 
containing 10 mM imidazole, and transferred into a column. Beads were washed with 2 
mL of wash buffer (50 mM HEPES [pH 7.4], 150 mM NaCl, 3 mM b-mercaptoethanol, 10 
mM imidazole, 0.01% Igepal CA-630, 10% glycerol), and MEK1 was eluted in 150 µL 
fractions with wash buffer + 250 mM imidazole. The two most concentrated fractions as 
determined by Bradford assay (Bio-Rad, 5000006) were combined and dialyzed 
overnight at 4°C into 20 mM HEPES [pH 7.4], 150 mM NaCl, 1 mM DTT, 10% glycerol, 
0.01% Igepal CA-630. Protein concentration was estimated from Coomassie-stained 
10% polyacrylamide gels using a BSA standard curve 
 To prepare PP6 complexes, HEK293T cells were co-transfected in 15 cm plates 
with 4 µg pFLAG-PPP6C, 8.6 µg pV1900-PPP6R3 and 8.6 µg pV1900-ANKRD28 pre-
complexed with 63.3 µg PEI. Cells were lysed 40 hours post-transfection after washing 
with cold PBS in 2.25 µL CHAPS lysis buffer (50 mM Tris [pH 7.5], 150 mM NaCl, 0.3% 
CHAPS, 1 mM PMSF, 10 µg/mL leupeptin, 2 µg/mL pepstatin A, 10 µg/mL aprotinin) per 
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plate. Lysates were cleared as above, and M2 anti-FLAG affinity gel (33 µL per plate) 
was added to the supernatant. Samples were rotated at 4 °C for 1 hr, and beads were 
pelleted, washed three times with lysis buffer (0.3 mL per plate) and once with wash 
buffer (50 mM HEPES, pH 7.4, 150 mM NaCl, 10% glycerol). Protein was eluted in two 
rounds with 30 uL wash buffer + 0.5 mg/mL 3xFLAG peptide (Sigma F4799) per plate, 
snap frozen on dry ice/EtOH and stored at -80 °C. Protein concentration was estimated 
from Coomassie-stained 10% polyacrylamide gels using a BSA standard curve.  
 ERK2 was purified in unphosphorylated from bacteria as described in 310.  ERK2 
(21 µM) was phosphorylated in vitro by incubation with 0.2 µM bacterially-expressed 
active His6-MEK1DE102-I103 in kinase reaction buffer (50 mM Tris [pH 8.0], 50 mM NaCl, 0.5 
mM ATP, 1mM DTT, 0.01% Igepal CA-630, 10% glycerol, 10 mM MgCl2) at 30°C for 30 
min. MEK1 was removed by adding 20 µL Talon resin, rotating at 4°C for 1 h, and filtered 
through a chromatography column.  
 
BRAF IP Kinase Assay 
Protocol for BRAF IP kinase assays was adapted from 312. Confluent 10 cm plates of 
shCTRL, shPPP6C-1, or shPPP6C-2 expressing 501mel cells were washed twice with 
cold PBS and lysed in RIPA buffer (20 mM Tris [pH 8.0], 137 mM NaCl, 10% glycerol, 
1% NP-40, 1 mM PMSF, 1 mM Na3VO4, 10 µg/mL leupeptin, 2 µg/mL pepstatin A, 10 
µg/mL aprotinin, 0.1% SDS, 0.5% sodium deoxycholate) on ice for 15 min. Cells were 
scraped into 1.5 mL tubes and lysates were passed through 22G needle with a syringe 
3 times. Lysates were clarified in a 4°C microcentrifuge at 13,000 rpm for 10 min. Lysates 
were analyzed by BCA protein assay and equivalent amounts of protein were pre-
cleared for 1 hour at 4°C with nProtein A Sepharose 4 Fast Flow beads (Sigma, GE17-
5280-01) pre-equilibrated with lysis buffer. Beads were removed and lysates were 
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divided into 500 µL aliquots containing 500 µg protein for each assay condition or 
timepoint. Antibody to BRAF (7.5 µL) was added to each sample, and tubes were rotated 
2 h at 4°C. To precipitate immune complexes, 50 µL of a 1:1 suspension of nProtein A 
Sepharose in lysis buffer was added, and tubes again rotated for 2 h at 4°C. Beads were 
pelleted, washed three times with lysis buffer, and resuspended in kinase reaction buffer 
(20 mM Tris [pH 7.4], 20 mM NaCl, 1 mM DTT, 10 mM MgCl2, 1 mM MnCl2). Purified 
unphosphorylated MEK1 (0.5 µg) and/or vemurafenib (to 1 µM) were added to as 
indicated. To initiate kinase reactions, ATP was added to a final concentration of 1 mM 
and volume of 40 µL, and tubes were transferred to 30°C heat block for the indicated 
times. Reactions were quenched with 4X SDS-PAGE loading buffer and boiled for 5 
minutes and then subjected to SDS-PAGE (10% acrylamide) and immunoblotting as 
described above.  
 
siRNA Transfection 
Cells plated in 6-well plates were transfected with siRNA using Lipofectamine RNAiMAX 
reagent (Thermo Fisher Scientific, 13778100). Equal parts siRNA oligonucleotides (100 
nM in 1X siRNA buffer, Horizon Discovery) and Lipofectamine RNAiMAX (diluted 1:100 
in Opti-MEM Medium) were combined and incubated for 15 minutes at room 
temperature. Lipofectamine:siRNA complexes (400 µL) and complete media (600 µL) 
were added to each well. Cells were incubated for 72 h before being lysed for 
immunoblot analysis as described above. For cells transfected with two different siRNAs, 
half the amount of each siRNA was used. 
 
In Vitro Phosphatase Assays 
For each reaction, PP6 complex containing 125 ng PPP6C and 500 ng phosphorylated 
MEK were mixed in 30 µL reaction buffer (50 mM Tris-HCl [pH8.0], 0.5 mM MnCl2, 2 mM 
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DTT) with or without 100nM okadaic acid as indicated. Reactions were incubated at 30 
°C for the indicated time, quenched by the addition of 4X SDS-PAGE loading buffer, and 
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